Connect public, paid and private patent data with Google Patents Public Datasets

Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Download PDF

Info

Publication number
USRE37721E1
USRE37721E1 US09594996 US59499600A USRE37721E US RE37721 E1 USRE37721 E1 US RE37721E1 US 09594996 US09594996 US 09594996 US 59499600 A US59499600 A US 59499600A US RE37721 E USRE37721 E US RE37721E
Authority
US
Grant status
Grant
Patent type
Prior art keywords
ar
formula
ch
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US09594996
Inventor
Stuart B. Rosenblum
Sundeep Dugar
Duane A. Burnett
John W. Clader
Brian A. McKittrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme Corp
Original Assignee
Merck Sharp & Dohme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date
Family has litigation

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of products other than chlorine, adipic acid, caprolactam, or chlorodifluoromethane, e.g. bulk or fine chemicals or pharmaceuticals
    • Y02P20/55Synthetic design, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/824Arteriosclerosis

Abstract

Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula
or a pharmaceutically acceptable salt thereof, wherein:
Ar1 and Ar2 are aryl or R4-substituted aryl;
Ar3 is aryl or R5-substituted aryl;
X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—;
R and R2 are —OR6, —O(CO)R6, —O(CO)OR9 or —O(CO)NR6R7;
R1 and R3 are H or lower alkyl;
q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5;
R4 is selected from lower alkyl, R5, —CF3, —CN, —NO2 and halogen R5 is selected from —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, —(lower alkylene)COOR6 and —CH═CH—COOR6;
R6, R7 and R8 are H, lower alkyl or aryl-substituted Ic
R9 is lower alkyl, aryl or aryl-substituted lower alkyl;
are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.

Description

The present application is the United States national application corresponding to International Application No. PCT/US94/10099, filed Sep. 14, 1994 and designating the United States, which PCT application is in turn a continuation-in-part of U.S. application Ser. No. 08/257593, filed Jun. 9, 1994, U.S. Pat. No. 5,631,365, which is a continuation-in-part of U.S. application Ser. No. 08/102,440, filed Sep. 21, 1993, abandoned.

BACKGROUND OF THE INVENTION

The present invention relates to hydroxy-substituted azetidinones useful as hypocholesterolemic agents in the treatment prevention of atherosclerosis, and to the combination of a hydroxy-substituted azetidinone of this invention and a cholesterol bioxynthesis inhibitor for the treatment and prevention of atherosclerosis. The invention also relates to a process for preparing hydroxy-substituted azetidinones.

Atherosclerotic coronary heart disease (CHD) represents the major cause for death and cardiovascular morbidity in the western world. Risk factors for atherosclerotic coronary heart disease include hypertension, diabetes mellitus, family history, male gender, cigar smoke and serum cholesterol. A total cholesterol level in excess of 225-250 mg/dl is associated with significant elevation of risk of CHD.

Cholesteryl esters are a major component of atherosclerotic lesions and the major storage form of cholesterol in arterial wall cells. Formation of cholesteryl esters is also a key step in the intestinal absorption of dietary cholesterol. Thus, inhibition of cholesteryl ester formation and reduction of serum cholesterol is likely to inhibit the progression of atherosclerotic lesion formation, decrease the accumulation of cholesteryl esters in the arterial wall, and block the intestinal absorption of dietary cholesterol.

A few azetidinones have been reported as being useful lowering cholesterol and/or in inhibiting the formation of cholesterol-containing lesions in mammalian arterial walls. U.S. Pat. No. 4,983,597 discloses N-sulfonyl-2-azetidinones as anticholesterolemic agents and Ram, et al., in Indian J. Chem., Sect. B. 29B, 12 (1990), p. 1134-7, disclose ethyl 4-(2-oxoazetidin-4-yl)phenoxy-alkanoates as hypolipidemic agents. European Patent Publication 264,231 discloses 1-substituted-4-phenyl-3-(2-oxo-alkylidene)-2-azetidinones as blood platelet aggregation inhibitors. European Patent 199,630 and European Patent Application 337,549 disclose elastase inhibitory substituted azetidinones said to be useful treating inflammatory conditions resulting in tissue destruction which are associated with various disease states, e.g. atherosclerosis.

WO93/102048, published Feb. 4, 1993, discloses substituted β-lactams useful as hypocholesterolemic agents.

The regulation of whole-body cholesterol homeostasis in humans and animals involves the regulation of dietary cholesterol and modulation of cholesterol biosynthesis, bile acid biosynthesis and the catabolism of the cholesterol-containing plasma lipoproteinis. The liver is the major organ responsible for cholesterol biosynthesis and catabolism and for this reason, it is a prime determinant of plasma cholesterol levels. The liver is the site of synthesis and secretion of very low density lipoproteins (VLDL) which are subsequently metabolized to low density lipoproteins (LDL) in the circulation. LDL are the predominant cholesterol-carrying lipoproteins in the plasma and an increase in their concentration is correlated with increased atherosclerosis.

When intestinal cholesterol absorption is reduced, by whatever means, less cholesterol is delivered to the liver. The consequence of this action is decreased hepatic lipoprotein (VLDL), production and an increase in the hepatic clearance of plasma cholesterol, mostly as LDL. Thus, the net effect of inhibiting intestinal cholesterol absorption is a decrease in plasma cholesterol levels.

The inhibition of cholesterol biosynthesis by 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase (EC1.1.1.34) inhibitors has been shown to be an effective way to reduce plasma cholesterol (Witzum, Circulation, 80, 5 (1989), p. 1101-1114) and reduce atherosclerosis. Combination therapy of an HMG CoA reductase inhibitor and a bile acid sequestrant has been demonstrated to be more effective in human hyperlipidemic patients than either agent in monotherapy (Illingworth, Drugs, 36 (Suppl. 3) (1988), p. 63-71).

SUMMARY OF THE INVENTION

Novel hypocholesterolemic compounds of the present invention are represented by the formula I

or a pharmaceutically acceptable salt thereof, wherein:

Ar1 and Ar2 are independently selected from the group consisting of aryl and R4-substituted aryl;

Ar3 is aryl or R5-substituted aryl;

X, Y and Z are independently selected from the group consisting of —CH2—, —CH(lower alkyl)— and —C(dilower alkyl)—;

R and R2 are independently selected from the group consisting of —OR6, —O(CO)R6, —O(CO)OR9 and —O(CO)NR6R7;

R1 and R3 are independently selected from the group consisting of hydrogen, lower alkyl and aryl;

q is 0 or 1; r is 0 or 1; m, n and p are independently 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q are r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4, or 5;

R4is 1-5 substituents independently selected from the group consisting of lower alkyl, —OR6, —O(CO)R6, R6 , —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO) NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, —(lower alkylene)COOR6, —CH═CH—COOR6, —CF3, —CN, —NO2 and halogen;

R5 is 1-5 substituents independently selected from the group consisting of —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO) R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, —(lower alkylene)COOR6 and —CH═CH—COOR6;

R6, R7 and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and

R9 is lower alkyl, aryl or aryl-substituted lower alkyl.

R4 is preferably 1-3 independently selected substituents, and R5 is preferably 1-3 independently selected substituents. Preferred are compounds of formula I wherein Ar1 is phenyl or R4-substituted phenyl, especially (4-R4)-substituted phenyl, Ar2 is preferably phenyl or R4-substituted phenyl, especially (4-R4)-substituted phenyl. Ar3 is preferably R5-substituted phenyl, especially (4-R5)-substituted phenyl. When Ar1 is (4-R4)-substituted phenyl, R4 is preferably a halogen. When Ar2 and Ar3 are R4- and R5-substituted phenyl, respectively, R4 is preferably halogen or —OR6 and R5 is preferably —OR6, wherein R6 is lower alkyl or hydrogen. Especially preferred are compounds wherein each of Ar1 and Ar2 is 4-fluorophenyl and Ar3 is 4-hydroxyphenyl or 4-methoxyphenyl.

X, Y and Z are each preferably —CH2—.R1 and R3 are each preferably hydrogen. R and R2 are preferably —OR6 wherein R6 is hydrogen, or a group readily metabolizable to a hydroxyl (such as —O(CO)R6, —O(CO)OR9 and —OR6, especially —O(CO)NR6R7, defined above).

The sum of m, n, p, q and r is preferably 2, 3 or 4, more preferably 3. Preferred are compounds wherein m, n and r are each zero, q is 1 and p is 2. Also preferred are compounds wherein p, q and n are each zero, r is 1 and m is 2 or 3. More preferred are compounds wherein m, n and r are each zero, q is 1, p is 2, Z is —CH2 and R is —OR6OR6, especially when R6 is hydrogen. Also more preferred are compounds wherein p, q and n are each zero, r is 1, m is 2, X is —CH2— and R2 is —OR6, especially when R6 is hydrogen.

Another group of preferred compounds is that wherein Ar1 is phenyl or R4-substituted phenyl, Ar2 is phenyl or R4-substituted phenyl and Ar3 is R5-substituted phenyl. Also preferred are compounds wherein Ar1 is phenyl or R4-substituted phenyl, Ar2 is phenyl or R4-substituted phenyl, Ar3 is R5-substituted phenyl, and the sum of m, n, p, q and r is 2, 3 or 4, more especially 3. More preferred are compounds wherein Ar1 is phenyl or R4-substituted phenyl, Ar2 is phenyl or R4-substituted phenyl Ar3 is R5-substituted phenyl, and wherein m, n and r are each zero, q is 1 and p is 2, or wherein p, q and n are each zero, r is 1 and m is 2 or 3.

This invention also relates to a method of lowering the serum cholesterol level in a mammal in need of such treatment comprising administering an effective amount of a compound of formula I. That is, the use of a compound of the present invention as an hypocholesterolemic agent is also claimed.

In still another aspect, the present invention relates to a pharmaceutical composition comprising a serum cholesterol-lowering effective amount of a compound of formula I in a pharmaceutically acceptable carrier.

The present invention also relates to a method of reducing plasma cholesterol levels, and to a method of treating or preventing atherosclerosis, comprising administering to a mammal in need of such treatment an effective amount of a combination of a hydroxy-substituted azetidinone cholesterol absorption inhibitor of formula I and a cholesterol biosynthesis inhibitor. That is, the present invention relates to the use of a hydroxy-substituted azetidinone cholesterol absorption inhibitor of formula I for combined use with a cholesterol biosynthesis inhibitor (and, similarly, use of a cholesterol biosynthesis inhibitor for combined use with a hydroxy-substituted azetidinone cholesterol absorption inhibitor of formula I) to treat or prevent atherosclerosis or to reduce plasma cholesterol levels.

In yet another aspect, the invention relates to a pharmaceutical composition comprising an effective amount of a hydroxy-substituted azetidinone cholesterol absorption inhibitor of formula I, a cholesterol biosynthesis inhibitor, and a pharmaceutically acceptable carrier. In a final aspect, the invention relates to a kit comprising in one container an effective amount of a hydroxy-substituted azetidinone cholesterol absorption inhibitor of formula I in a pharmaceutically acceptable carrier, and in a separate container, an effective amount of a cholesterol biosynthesis inhibitor in a pharmaceutically acceptable carrier.

In yet another aspect, the invention relates to a process for preparing certain compounds of formula I comprising the steps:

(a) treating with a strong base a lactone of the formula

wherein R′ and R2′ are R and R2, respectively, or are suitably protected hydroxy groups; Ar10 is Ar1, a suitably protected hydroxy substituted aryl or a suitably protected amino-substituted aryl; and the remaining variables are as defined above, provided that in lactone of formula B when n and r are each zero, p is 1-4;

(b) reacting the product of step (a) with an imine of the formula

wherein Ar20 is Ar2, a suitably protected hydroxy-substituted aryl or a suitably protected amino-substituted aryl; and Ar30 is Ar3, a suitably protected hydroxy-substituted aryl or a suitably protected amino-substituted aryl;

c) quenching the reaction with an acid;

d) optionally removing the protecting groups from R′, R2′, Ar10, Ar20 and Ar30, when present; and

e) optionally functionalizing hydroxy or amino substituents at R, R2, Ar1, Ar2 and Ar3.

Using the lactones shown above, compounds of formula IA and IB are obtained as follows:

wherein the variables are as defined above; and

wherein the variables are as defined above.

DETAILED DESCRIPTION

As used herein, the term “lower alkyl” means straight or branched alkyl chains of 1 to 6 carbon atoms.

“Aryl” means phenyl, naphthyl, indenyl, tetrahydronaphthyl or indanyl.

“Halogen” refers to fluorine, chlorine, bromine or iodine atoms.

The above statement, wherein R6, R7 and R8 are said to be independently selected from a group of substituents, means that R6, R7 and R8 are independently selected, but also that where an R6 , R6 or R8 variable occurs more than once in a molecule, those occurrences are independently selected (e.g., if R is —OR6 wherein R6 is hydrogen, R4 can be —OR6 wherein R6 is lower alkyl).

Compounds of the invention have at least one asymmetric carbon atom and therefore all isomers, including enantiomers and diastereomers are contemplated as being part of this invention. The invention includes d and I l isomers in both pure form and in admixture including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting chiral starting materials or by separating isomers of a compound of formula I. Isomers may also include geometric isomers, e.g. when a double bond is present. All such geometric isomers are contemplated for this invention.

Those skilled in the art will appreciate that for some compounds of formula I, one isomer will show greater pharmacological activity than another isomer.

Compounds of the invention with an amino group can form pharmaceutically acceptable salts with organic and inorganic acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art. The salt is prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt. The free base form may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium bicarbonate. The free base form differs from its respective salt form somewhat in certain physical properties, such as solubility in polar solvents, but the salt is otherwise equivalent to its respective free base form for purposes of the invention.

Certain compounds of the invention are acidic (e.g., those compounds which possess a carboxyl group). These compounds form pharmaceutically acceptable salts with inorganic and organic bases. Examples of such salts are the sodium, potassium, calcium, aluminum, gold and silver salts. Also included are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.

Cholesterol biosynthesis inhibitors for use in the combination of the present invention include HMG CoA reductase inhibitors such as lovastatin, pravastatin, fluvastatin, simvastatin, and Cl-981; HMG CoA synthetase inhibitors, for example L-659,699 ((E,E)-11-[3′-R-(hydroxy-methyl)-4′-oxo-2′-R-oxetanyl]-3,5,7R-trimethyl-2,4-undecadienoic acid); squalene synthesis inhibitors, for example squalestatin 1; and squalene epoxidase inhibitors, for example, NB-598 ((E)-N-ethyl-N-(6,6-dimethyl-2-hepten-4-ynyl)-3-[(3,3′-bithiophen-5-yl)methoxy]benzene-methanamine hydrochloride) and other cholesterol biosynthesis inhibitors such as DMP-565. Preferred HMG CoA reductase inhibitors are lovastatin, pravastatin and simvastatin.

Compounds of formula I can be prepared by known methods, for example those described below and in WO93/02048.

Compounds of formula Ia and Ib, wherein Ar1, Ar2, Ar3, Ar 3 X, Y, Z, R1, R2, R3, m, n, p, q and r are as defined above, can be prepared by treatment of an ester of formula III, wherein R10 is lower alkyl such as ethyl or a chiral moiety such as menthyl or 10-(diisopropylsulfonamido)isobornyl, and the remaining variables are as defined above, with a strong base such as lithium diisopropylamide (LDA) in a suitable solvent such as tetrrahydrolithium (THF) at −78° C. A solubilizing agent such as hexamethylphosphoric triamide (HMPA) may optionally be added as a cosolvent. An imine of formula 11, wherein Ar20 and Ar30 are as defined above, is added, the reaction mixture is either warmed to room temperature or maintained at a suitable low temperature such as −78° C. for the appropriate time, followed by quenching with a suitable acid such as 1N HCl. The product is isolated using conventional purification techniques. When a protecting group as defined in Table 1 (below) is present on one or more of the optionally protected groups, an additional step comprising removal of the protecting group by conventional techniques is needed. However, for compounds of formula Ia, Ib, or any compound of formula I wherein a protected hydroxy group Ar10, Ar20, Ar30, R′ or R2′ is an alkoxy or benzyloxy group, such a protecting group need not be removed to obtain a compound of formula I. When a chiral ester of formula III is used, the resulting compound of formula Ia or Ib is not racemic.

Imines of formula II (Ar30—CH═N—Ar20) can be prepared from aldehydes of the formula Ar30—CHO and amines of the formula Ar+—CHO and Ar20 —NH 2 by procedures well known in the art. Aldehydes of formula Ar+Ar30—CHO and amines of formula Ar20—NH2 are commercially available or can be prepared via known procedures.

Compounds of formula Ic and Id, wherein the variables are as defined above, can be prepared by a process comprising the following steps:

(a) Treat a lactone of formula IV, wherein the variables are as defined above, with a strong base such as an alkyllithium (e.g., n-butyl-lithium), a metal hydride (e.g., sodium hydride), a metal alkoxide (e.g., sodium methoxide), a metal halide (e.g., TiCl4), metal exchange of the lithium enolate with a metal halide (e.g., zinc chloride), metal exchange of the lithium enolate with a metal alkyl (e.g., 9-borabicyclononyl triflate), or, preferably, a metalamide (e.g., LDA), in a suitable anhydrous organic solvent such as dry THF, ether or benzene, in a dry, inert atmosphere, e.g., under nitrogen. The reaction is carried out at about 0° C. to about −85° C., preferably about −78° C., over a period of about 5 to about 60 minutes, preferably about 30 minutes. 1-50% of solubilizing cosolvents may optionally be added, preferably about 10% HMPA.

(b) Add an imine of formula 11, wherein Ar20 and Ar30 are as defined above, to the product of step (a) over a period of 5 to 60 minutes, preferably 30 minutes, maintaining the reaction mixture at about 0° C. to about −85° C., preferably about −78° C., for 1 to 12 hours, preferably about 3 hours, or warming the reaction mixture over that time period at a rate of about 10° C. per hour to about 70° C. per hour, preferably about 30° C. per hour, to a temperature of about 20° C.

(c) Quench the reaction with a suitable acid such as HCl (1N).

(d) The protecting groups on R′, R2′, Ar10, Ar20 and Ar30, when present, are removed, if desired, by methods well known in the art, for example silyl protecting groups are removed by treatment with fluoride.

e) Compounds of formula I wherein any of R and R2, when present, are OR6 wherein R6 is hydrogen, can be converted by well known methods to other compounds of formula I wherein R and R2 are functionalized, i.e., are independently selected from the group consisting of OR6a, —O(CO)R6, —O(CO)OR9 and —O(CO)NR6R7, wherein R6, R7 and R9 are as defined above and R6a is lower alkyl, aryl, or aryl-lower alkyl. For example, treatment of the alcohol with an alkyl halide in the presence of a suitable base such as NaH will afford alkoxy-substituted compounds (i.e., R or R2 is OR6, wherein R6 is lower alkyl); treatment of the alcohol with an acylating agent such as acetylchloride will result in compounds wherein R or R2 is —OC(O)R6; treatment of the alcohol with phosgene followed by an alcohol of the formula HOR9 affords compounds substituted with a —OC (O)OR9 group; and treatment of the alcohol with phosgene followed by an amine of the formula HNR6R7 affords compounds wherein R or R2 is —OC(O)NR6R7. Compounds of formula I wherein any Ar1, Ar2 or Ar3 has a hydroxy or amino group can be similarly functionalized to obtain other compounds of formula 1, i.e., wherein R4 and R5 are independently —OR6a, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO) R7, —NR6(CO)OR9, —NR6(CO)NR7R8 or —NR6SO2R9.

The product of step c, d or e is isolated using conventional purification techniques such as extraction, crystallization or, preferably, silica gel 60 chromatography. When a chiral lactone is used, the resulting compound of formula Ic or Id is not racemic.

Using the procedure described in steps (a)-(e), lactones of formula IVa can be used to prepare compounds of formula Ig and Ih, provided that when n and r are each zero, p is 1-4:

Lactones of formulae IV and IVa are known in the art or can be prepared by methods well known in the art. See, for example, U.S. Pat. No. 4,375,475 and J. Agric. Food Chem., 30 (5) (1982) p. 920-4.

Azetidinones of formula V, wherein Ar20 and Ar30 are as defined above, can be reacted to form compounds of formula Ie and If i.e., compounds of formula I wherein r is 1, R2 is hydroxy, and p is zero) by treatment of azetidinone V with a strong base such as lithium iosoproptylcyclohexylamide isopropylcyclohexylamide in a suitable solvent such as THF in the presence or absent absence of HMPA at −78° C., followed by the addition of an aldehyde or ketone of VI, wherein Ar10, X, Y, R′, R1, R3, m, n and q are as defined above. As in the case of Method A, protecting groups at Ar10, Ar20, Ar30, R′ and R2′ are removed as necessary.

This process provides several of the possible diastereomers which can be separated by a combination of crystallization, silica gel chromatography and HPLC, using techniques well known in the art. The remaining diastereomers can be obtained by inversion reactions such as the Mitsunobu reaction sequence outlined below, wherein partial structures of formula If are shown:

In the above known process, DEAD is diethylazodicarboxylate and PPh3 is triphenylphosphine. The reactants are stirred at room temperature overnight and the resultant formate ester is converted to the corresponding hydroxy compound with the desired stereochemistry.

Compounds of formula Ia as defined above can be prepared by reacting a chiral auxiliary such as the compound of formula VIII with an activated carboxylic acid derivative of formula VII, for example an acid chloride (L═Cl), a mixed anhydride formed with phenyl phosphorodichloridate (L═OP(O)(Cl)OPh), an N-methyl-pyridinium ester formed from the reaction of an acid with N-methyl-2-chloropyridinium iodide (L=2-oxy-N-methylpyridinium iodide), and a 2-thiopyridyl ester formed from the reaction of an acid chloride and 2-thiopyridine, wherein the remaining variables are as defined above; enolizing the resultant product, for example with TiCl4 and tetramethylethylenediamine (TMEDA); condensing with an aldehyde, Ar30CHO; hydrolyzing to the corresponding acid, then reacting the compound of formula IX with an amine, Ar20NH2; and cyclizing the resultant compound of formula X, with, for example a trialkylphosphine and a dialkylazodicarbo)ylate. As in the case of Method A, protecting groups at Ar10, Ar20, Ar30, R′ and R2′ are removed as necessary. This procedure is described in detail in WO93/102048 WO93/02048.

Compounds of formula Ia as defined above can also be prepared treatment of an imine of formula 11, II, wherein Ar20 and Ar30 are as defined above, with an activated carboxylic acid derivative of formula VII as defined above in the presence of a tertiary amine base such as triethylamine, tributylamine or diethylisopropylamine in an inert solvent such as CH2Cl2. Again, as in the case of Method A, protecting groups at Ar10, Ar20, Ar30, R′ and R2′ are removed as necessary. Use of other bases, e.g., pyridine, favors formation of compounds of formula Ib.

In the first step, compound XII is dissolved in a suitable solvent, e.g., anhydrous CH2Cl2, and treated with a Lewis acid, e.g., TiCl4 at about −60° C. to 0° C., preferably at about −25° C., under a dry, inert atmosphere, e.g., argon. A tertiary amine base such as TMEDA is added and the mixture stirred at about −60° C. to 0° C., preferably at about −25° C. to −15° C., for a period of about 1 h. An imine of formula Ar30CH═NAr20 is added neat or optionally as a solution in a suitable solvent, e.g. anhydrous CH2Cl2, over a period of about 5 min, and the reaction is stirred vigorously at about −60° C. to 0° C., preferably at about −25° C. to −15° C., for about 3 to 6 h, preferably about 4 h or until the reaction is complete by TLC. An acid, e.g. acetic acid, is added to reaction at the reaction temperature and the mixture is allowed to warm to room temperature slowly with stirring for about 1-3 hours, preferably about 2 hours. The compound of formula XII is isolated by extraction with a suitable solvent, e.g. CH2Cl2, then purified by crystallization or silica gel chromatography.

In the second step, the product is treated with a strong non-nucleophilic base, such as sodium or lithium bistrimethylsilylamide at about −78° C. to 100° C. After reaction, the mixture is poured into aqueous tartaric acid and the product isolated from the organic layer. As in the case of Method A, protecting groups at Ar10, Ar20, Ar30, R′ and R2′ are removed as necessary. This process, including the preparation of the starting material of formula XII, is also described in greater detail in WO93/02048.

Compound of formula Ig′ and Ih′ (i.e., compounds of formula I wherein R is OH), wherein R2′ is a protected hydroxy group as defined above, and the remaining variables are as defined above, can be prepared by reacting an imine of formula 11II and a carboxylic acid derivative of formula XIV, wherein the variables are as defined above, according to Method D, followed by oxidation of the resultant halide of formula XV by treatment with an oxidizing agent such as trimethylamine oxide, CrO3 or ozone in a solvent such as DMSO. The resultant aldehyde or ketone of formula XVI is then reacted with an aryl organometallic reagent (e.g., Ar10XmMgBr, Ar10XmLi, Ar10XmMgCl or Ar10XmCeCl2) to obtain a compound of formula Ig′ or Ih′. As described above, the Ar10, Ar20, Ar30 and R2′ substituents can be converted to the desired Ar1, Ar2, Ar3 and R2 substituents by procedures well known in the art.

Compounds of formula Ii having a hydroxy substituent on the side chain adjacent to the Ar1 group (i.e., compounds of formula I wherein m is 0) can be prepared by heating a compound of formula XVII, prepared by Method D, above, wherein the variables are as defined above, for about 1-6 hours at about 60° C. to 100° C. with a halogenating agent such as N-bromosuccinimide (NBS) in a suitable solvent such as CCl4 in the presence of an initiating agent such as benzoyl peroxide. The resultant compound of formula XVIII, wherein Hal is Cl, Br or I and the remaining variables are as defined above, is then heated in a suitable solvent such as CH2Cl2 with a tetraalkyl-ammonium salt such as tetra n-butyl-ammonium hydroxide (n-Bu4NOH) to obtain the compound of formula Ia. Alternatively, compound XVIII can be heated in a suitable solvent such as CH2Cl2 with tetra n-butylammonium trifluoroacetate (n-Bu4NOC(O)CF3) followed by treatment with a mild base such as ethanol saturated with NH3 NH 3 to obtain compound Ii,

Compounds of formula Ij (i.e., compounds of formula I wherein R is OH, R1 is H and q is 1) are prepared from compound XIX in 2 steps. First, a compound of formula XIX, wherein the variables are as defined above, is dissolved in a suitable anhydrous solvent, e.g. THF, at about −20° C. to about 22° C., preferably at about 0° C. under a dry inert atmosphere, e.g. argon and adding a transition metal source, e.g. tetrakis(triphenylphosphine)-palladium or palladium acetate/triphenyl phosphine. An organometallic of formula Ar10-Xm m-Met, wherein in Ar10, X and m are as defined above and Met is, for example, ZnCl or B(OH)2, is added to the reaction mixture at about −20° C. to about 22° C., preferably at about 0° C., the reaction mixture is stirred for about 15 min to 4 h, preferably about 1 h, and is then allowed to warm to about 22° C. Addition of dilute acid, e.g. 1N HCl, followed by extraction with a suitable organic solvent, e.g. ethyl acetate (EtOAc), produces compound XX.

The ketone of-formula XX is dissolved in a suitable solvent e.g. CH3OH, a hydrogenation catalyst is added, e.g. Pd on carbon, and the mixture is exposed to H2 gas under a pressure of about 14 psi to 100 psi, preferably about 60 psi for about 1 to 24 h, preferably, about 16 h. The hydrogenation catalyst is removed by filtration and the solvent is removed in vacuo to produce a compound Ij as a mixture of alcohol diastereomers which can be separated by conventional means.

Alternatively, a ketone of formula XX is dissolved in a suitable solvent, e.g. THF, at about −40° C. to about 22° C., preferably at about 0° C., and a suitable reducing agent such as NaBH4, a substituted borohydride (e.g., [cbz-proline] 3BHNa) or a borane is adlded, optionally in the presence of a suitable chiral promotor present either in catalytic or stoichiometric amounts, e.g., chiral borane of structures:

Addition of dilute acid, e.g., 1N HCl, followed by extraction with a suitable solvent produces compounds of formula Ij. As above, protecting groups at Ar10, Ar20, Ar30 and R2′ are removed as necessary. When either a chiral reagent or a chiral promotor is used, the resulting product is non-racemic.

Compounds of formula XIX can be prepared by a multi-step procedure as represented below:

Compounds of formula XXI, wherein R10 is lower alkyl and the remaining variables are as defined above, are commercially available or can be prepared by treating the corresponding carboxylic acid (i.e., compounds wherein the Cl is replaced by a hydroxy group) with a chlorinating agent, e.g. SOCl 2 or oxalyl chloride, under a dry atmosphere, neat or in a suitable inert organic solvent, e.g. toluene at about 40° C. to 110° C., preferably about 70° C.; alternatively, a catalyst made be added, e.g. dimethylformamide (DMF), the reaction is conducted at about 22° C., and the solvent and excess reagents are removed in vacuo. The compound XXI is reacted with a chiral auxiliary such as (S)- 4 -phenyl- 2 -oxazolidinone according to the following procedure; a chiral auxiliary is treated with a strong base such as an alkyllithium, a metal hydride or a tertiary amine base such as triethylamine, in a suitable anhydrous organic solvent, e.g., dry THF, under a dry, inert atmosphere, e.g. argon at about −85° C., to 22° C., preferably about 0° C., for about 10 min to 60 min, preferably about 30 minutes. The resulting anion is reacted, without isolation, with compound XXI in a suitable anhydrous organic solvent, e.g. dry THF, under a dry, inert atmosphere, e.g. argon at about −85° C. to about 22° C., preferably 0° C., for about 30 min to 60 min, preferably 30 min. The reaction is warmed to about 22° C. and continued for 1 to 12 h, preferably 6 h. Water is added and compound XXII is isolated by extraction and purified by crystallization.

The compound of formula XXII is treated in the same manner as described in step 1 of Method E to obtain a compound XXIII.

Azetidinone ring closure can be accomplished by alternative procedures. By one method, a compound of formula XXIII is treated with a strong non-nucleophilic base, such as sodium or lithium-bistrimethylsilylamide, in a suitable inert organic solvent, e.g. CH2Cl2, at about −78° C. to about 10° C., preferably about 0° C. The mixture is stirred for about 1 to 2 hours while gradually warming to about 22° C. Compound XXIV is isolated by conventional extraction with CH2Cl2. In another, two-step method, a compound of formula XXIII is first treated with mild silylating agent, e.g. N,O-bis(trimethylsilyl)acetamide at about 0° C. to about 100° C., preferably about 40° C. for about 10 min to 60 min, preferably 30 min, then treated with a fluoride anion source, e.g. tetrabutylammonium fluoride (TBAF), at about 0° C. to about 100° C., preferably 40° C., and allowed to stir for about 0.5 to about 4 hours, preferably about 2 hours. Compound XXIV is isolated by conventional extraction methods.

The compound of formula XXIV is hydrolysed by a suitable base, e.g. LiOH, in a suitable solvent, e.g. 66% CH3OH/water at about 0° C. to about 50° C., preferably 22° C., for about 1 to 4 hours, preferably 2 hours, then extracted with a suitable solvent, e.g. EtOAc. The resulting acid is converted to the acid chloride as described above by treatment with a chlorination agent, e.g. oxalyl chloride, to afford compound

Compounds of formula Ik, wherein Ar1, Ar2, Ar3 and R1 are as defined above, one of X″ and Y″ is —CH2CH2— and the other is selected from the group consisting of —CH2CH2—, —CH2—, —CH(lower alkyl)-, —CH (dilower alkyl) and a bond, are prepared by oxidation of an alkene of formula XXV, wherein one of X′ and Y′ is —CH═CH— and the other is —CH═CH—, —CH2—, —CH2CH2—, —CH(lower alkyl)-, —CH(dilower alkyl) or a bond, and the remaining variables are as defined above, can be prepared by the following two step procedure.

A compound of formula XXV, which can be prepared by Method D, above, is treated with an oxidizing agent such as SeO2, phenylselenic anhydride or CrO3 in a suitable solvent such as dioxane at about 22° to 100° C. for about 0.5 to 12 hours. After the starting material is consumed as determined by TLC, or 12 hours, the reaction is cooled to about 22° C. and the product XXVI is isolated by extraction.

In the second step, an allylic alcohol of formula XXVI is dissolved in a suitable solvent, e.g., EtOAc, a hydrogenation catalyst added, e.g., Pd on carbon, and the mixture is exposed to H2 gas under a pressure of about 14 psi to 60 psi for about 1 to 12 hours. The hydrogenation catalyst is removed in vacuo to obtain a compound of formula Ik.

Alcohols of formula Im and In (i.e., compounds of formula I where r is 1, R2 is —OH, R3 is hydrogen and p is 0) can be selectively obtained from ketones of formula XXVII in three steps comprising bromination, reduction and debromination. Since the stereochemistry of the major isomers of alcohols XXIXa and XXIXb are different, one can selectively prepare either diastereomeric alcohol.

In the above process, a ketone of formula XXVII, which can be prepared by oxidation of the corresponding hydroxy compound by well known methods, is halogenated, for example by treatment in an inert solvent, e.g., THF, with NaH followed by N-bromosuccinimide, to obtain a mixture of 3-bromo-ketone compounds XXVIII (a and b). Compounds 15 XXVIIIa and XXVIIIb are then separately reduced to the corresponding alcohols, for example by treatment with magnesium trifluoroacetate (Mg(TFA)2) and t-butylamine borane (t-Bu—NH2—BH3) in an inert solvent such as THF at a temperature of about −78° C. to 0° C. The resultant alcohols XXIX are dehalogenated by treatment with tris(trimethylsilyl)silane ((TMS)3SiH) in a solvent such as toluene in the presence of a radical initiator such as 2,2′-azobisisobutyronitrile (AIBN) to obtain a mixture of isomers Im and In which can be separated into individual enantiomers by conventional means, e.g., HPLC. Again, protecting groups at Ar10, Ar20, Ar30 and R′ are removed as necessary.

Starting compounds III, V, VI, VII, VIII, XIV, XVII, XXI and XXV are all either commercially available or well known in the art and can be prepared via known methods.

Reactive groups not involved in the above processes can be protected during the reactions with conventional protecting groups which can be removed by standard procedures after the reaction. The following Table 1 shows some typical protecting groups:

TABLE 1
Group to be Group to be Protected and
Protected Protecting Group
—COOH —COOalkyl, —COObenzyl, —COOphenyl
—NH2
—OH
—OSi(CH3)3, or —OCH2phenyl

We have found that the compounds of this invention lower serum lipid levels, in particular serum cholesterol levels. Compounds of this invention have been found to inhibit the intestinal absorption of cholesterol and to significantly reduce the formation of liver cholesteryl esters in animal models. Thus, compounds of this invention are hypocholesterolemic agents by virtue of their ability to inhibit the intestinal absorption and/or esterification of cholesterol; they are, therefore, useful in the treatment and prevention of atherosclerosis in mammals, in particular in humans.

The in vivo activity of the compounds of formula I can be determined by the following procedure:

In Vivo Assay of Hypoligidemic Hypolipidemic Agents Using the Hyperlipidemic Hamster

Hamsters are separated into groups of six and given a controlled cholesterol diet (Purina Chow #5001 containing 0.5% cholesterol) for seven days. Diet consumption is monitored to determine dietary cholesterol exposure in the face of test compounds. The animals are dosed with the test compound once daily beginning with the initiation of diet. Dosing is by oral gavage of 0.2 mL of corn oil alone (control group) or solution (or suspension) of test compound in corn oil. All animals moribund or in poor physical condition are euthanized. After seven days, the animals are anesthetized by intramuscular (IM) injection of ketamine and sacrificed by decapitation. Blood is collected into vacutainer tubes containing EDTA for plasma lipid analysis and the liver excised for tissue lipid analysis. Lipid analysis is conducted as per published procedures (Schnitzer-Polokoff, R., et al. Comp. Biochem. Physiol., 99A, 4 (1991), p. 665-670) and data is reported as percent reduction of lipid versus control.

The present invention also relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier. The compounds of formula I can be administered in any conventional dosage form, preferably an oral dosage form such as a capsule, tablet, powder, cachet, suspension or solution. The formulations and pharmaceutical compositions can be prepared using conventional pharmaceutically acceptable excipients and additives and conventional techniques. Such pharmaceutically acceptable excipients and additives include non-toxic compatible fillers, binders, disintegrants, buffers, preservatives, anti-oxidants, lubricants, flavorings, thickeners, coloring agents, emulsifiers and the like.

The daily hypocholesteremic dose of a compound of formula I is about 0.1 to about 30 mg/kg of body weight per day, preferably about 0.1 to about 15 mg/kg. For an average body weight of 70 kg, the dosage level is therefore from about 5 mg to about 1000 mg of drug per day, given in a single dose of 2-4 divided doses. The exact dose, however, is determined by the attending clinician and is dependent on the potency of the compound administered, the age, weight, condition and response of the patient.

For the combinations of this invention wherein the hydroxy substituted azetidinone is administered in combination with a cholesterol biosynthesis inhibitor, the typical daily dose of the cholesterol biosynthesis inhibitor is 0.1 to 80 mg/kg of mammalian weight per day administered in single or divided dosages, usually once or twice a day; for example, for HMG CoA reductase inhibitors, about 10 to about 40 mg per dose is given 1 to 2 times a day, giving a total daily dose of about 10 to 80 mg per day, and for the other cholesterol biosynthesis inhibitors, about 1 to 1000 mg per dose is given 1 to 2 times a day, giving a total daily dose of about 1 mg to about 200 mg per day. The exact dose of any component of the combination to be administered is determined by the attending clinician and is dependent on the potency of the compound administered, the age, weight, condition and response of the patient.

Where the components of a combination are administered separately, the number of doses of each component given per day may not necessarily be the same, e.g. where one component may have a greater duration of activity, and will therefore need to be administered less frequently.

Since the present invention relates to the reduction of plasma cholesterol levels by treatment with a combination of active ingredients wherein said active ingredients may be administered separately, the invention also relates to combining separate pharmaceutical compositions in kit form. That is, a kit is contemplated wherein two separate units are combined: a cholesterol biosynthesis inhibitor pharmaceutical composition and a hydroxy substituted azetidinone cholesterol absorption inhibitor pharmaceutical composition. The kit will preferably include directions for the administration of the separate components. The kit form is particularly advantageous when the separate components must be administered in different dosage forms (e.g. oral and parenteral) or are administered at different dosage intervals.

Following are examples of preparing compounds of formula I. The stereochemistry listed is relative stereochemistry unless otherwise noted. The terms cis and trans refer to the relative orientations at the azetidinone 3- and 4-positions unless otherwise indicated. The term “J” refers to the proton NMR coupling constant in hertz (Hz) between the 3- and 4-substituted protons of the azetidinone. All NMR data is of CDCl3 solution unless otherwise indicated.

Freshly prepare a solution of lithium diisopropylamide (LDA) by dissolving diisopropylamine (1.19 g, 11.8 mmol) in anhydrous THF (20 ml) at −78° C. under argon. Add n-butyllithium (4.9 ml, 11.8 mmol, 2.4M in hexanes) and stir for 0.5 h at −78° C. To this cold solution add, 4phenylbutyrolactone (1.75 g, 10.8 mmol) in THF (4 ml) over 0.25 h, keeping the reaction temperature below −65° C. Stir at −78° C. for 0.25 h, then add 4-methoxybenzylidine anisidine (2.33 g, 11.0 mmol) in THF (8 ml) over 1 h at −78° C. Warm the reaction slowly to −50° C. over 1 h. Quench the reaction at low temperature with 1N HCl (12 ml). Partition the reaction mixture between ether and 1N HCl, wash the ether layer with water, combine the ether extracts, dry over MgSO4 and concentrate in vacuo. Crystallize the crude reaction residue (3.0 g) from EtOAc-ether to obtain 1.54 g of compound A. Reconcentrate the filtrate and chromatograph on silica gel 60, eluting with 4:1 EtOAc-hexane, and isolate additional compound A (0.385 g) as well as compound B (0.420 g).

Compound A: mp 218°-220° C.; IR 1730 cm-1; CI (M−H) 374; J=5.9 Hz.

Compound B: mp 74°-76° C.; IR 1730 cm-1; CI (M+H) 374; J=2.3 Hz.

Using a similar procedure and appropriate starting materials, prepare compound 1C:

Cl(M + H) 464, J = 2.3 Hz

EXAMPLE 2

To a solution of compound A from Example 1 (0.5 g, 1.3 mmol) in anhydrous pyridine (2.7 ml), add acetic anhydride (0.63 ml, 6.7 mmol). Stir for 16 h, dilute with CH2Cl2 and wash 3× with 1N HCl 1× with NaCI (sat'd) and 1× with water. Concentrate the organic layer to dryness and crystallize the residue from EtOAc to obtain the title compound (0.46 g), mp 167°-169° C.; IR 1745 cm-1; EI (M+) 415; J=5.9 Hz.

EXAMPLE 3

Freshly prepare a solution of lithium isopropylcyclohexylamide (LICA) by adding n-butyllithium (2.84 mL of a 1.6M solution) to 5 a solution of isopropylcyclohexylamine (0.75 mL) in THF (100 mL) at −78° C. Dissolve N-phenyl-4-(4-methoxyphenyl)-2-azetidinone (1.0 g) in THF (8 mL) and slowly add to the LICA solution at −78° C. After stirring for 20 min, add hydrocinnamaldehyde (0.54 g) and stir the reaction mixture at −78° C. for 4 h. Quench the reaction with 10% KHSO4 and extract the product with EtOAc. Separate the organic layer, wash with water and NaCl (sat'd). Concentrate the extract and purify the resultant residue on a silica gel 60 column, eluting with EtOAc:hexane (15:85) to obtain 1.15 g of product as a mixture of diastereomers. Separate the diastereomers by HPLC on a silica gel column to give three diastereomers 3A, 3B and 3C:

3A 1H in CDCl3:7.32-7.18(m, 11H); 7.08-6.99 (m, 1H); 6.89(d, J = 9 Hz, 2H); 4.80(d, J = 2.4 Hz, 1H); 4.10-4.00(m, 1H); 3.79(s, 3H); 3.20-3.16(m, 1H); 2.90-2.67(m, 2H); 2.15-1.85(m, 3H)
3B 1H in CDCl3:7.35-7.10(m, 11H); 7.08-6.99 (m, 1H); 6.89(d, J = 9 Hz, 2H); 5.09(d, J = 2.4 Hz, 1H); 4.26-4.14(m, 1H); 3.79(s, 3H); 3.21-3.14(m, 1H); 2.89-2.57(m, 2H); 2.10-1.85(m, 3H)
3C 1H in CDCl3:7.30-7.00(m, 10H); 6.99 (d, J = 8 Hz, 2H); 6.83(d, J = 9 Hz, 2H); 5.12(d, J = 5.5 Hz, 1H); 3.82(s, 3H); 3.75-3.63(m, 1H); 3.52(dd, J = 9.5 Hz, 1H); 2.71-2.57(m, 1H); 2.49-2.33(m, 1H); 1.68-1.50(m, 1H); 1.47-1.31)m, 1H)

The 3A, 3B and 3C, diastereomers were further separated according to the following reaction scheme, wherein partial structures are shown:

(The following CD spectra data [θ] are all obtained in CH3OH.)

3D) [θ]227nM=+2.0×104 cm2/dM; [θ]241nM=−4.6×104 cm2/dM. Elemental analysis calc for C25H25NO3−0.25 H2O: C 76.6; H 6.56 N 3.57. found: C 76.66; H 6.49; N 3.64.

3E) [θ]227nM=−1.95×104 cm2/dM; [θ]241nM=+4.45×104 cm2/dM. Elemental analysis calc for C25H25NO3.0.5 H2O: C 75.73; H 6.61; N 3.53. found: C 75.66; H 6.41; N 3.60.

3F) [θ]226nM=+1.97×104 cm2/dM; [θ]240nM=−5.22×104 cm2/dM. Elemental analysis calc for C25H25NO3: C 77.48; H 6.5-1; N 3.62. found: C 77.44; H 6.53; N 3.70.

3G) [θ]226nM=−1.78×104 cm2/dM; [θ]241nM=+4.78×104 cm2/dM (CIMS 388 M+H).

3H) [θ]226nM=+2.24×104 cm2/dM; [θ]241nM=−5.4×104 cm2/dM. [α]D 25=−54.4° (2.5 mg/ml CH3OH) Elemental analysis calc for C25H25NO3: C 77.48; H 6.51; N 3.62. found: C 77.11; H 6.50; N 3.72.

3I) [θ]226nM=−2.05×104 cm2/dM; [θ]241nM=+5.2×104 cm2/dM. (CIMS 388 M+H).

Add DEAD (0.11 ml) to a solution of compound 3H (132 mg), PPh3 (0.18 g) and HCO2H (39 ml) in THF (5 ml). Stir at room temperatq temperature overnight, then partition the reaction mixture between Et2O and H2O. Wash (brine) and dry (MgSO4) the organic layer and concentrate to dryness. Flash chromatograph the residue using EtOAc:Hex (1:4) to obtain the formate ester. Dissolve this in CH3OH and add 4 drops of conc. HCl. After 4 h, concentrate in vacuo and flash chromatograph the residue using EtOAc:Hex (1:3) to obtain 3J. [θ]224nM=+2.54×103 cm2/dM;

[θ]239nM=+5.70×104 cm2/dM; [α]D 20=−157.6° (2.5 mg/ml CH3OH)

Using the procedure described for 3J, treat compound 3I to obtain 3K. [θ]222nM=−3.4×103 cm2/dM; [α]240nM=−5.6×104 cm2/dM. [α]D 20=+167.2° (2.5 mg/ml CH3OH)

Using the procedure described above for preparing compounds 3A and 3B, treat N-phenyl-4-(4-methoxyphenyl)-2-azetidinone with LICA followed by 2-naphthaldehyde to obtain the diastereomers 3L and 3M:

3L mp 137- 138° C.
3M mp 150- 151° C.

EXAMPLE 4

Method 1:

Step 1) To a refluxing solution of of 4-methoxyberizylidene anisidine (10.0 g, 41.5 mmol) and tributylamine (20.8 ml, 87 mmol) in toluene (100 ml), add 5-bromovaleroyl chloride (8.5 g, 43, mmol) in toluene (20 ml) dropwise over 2 h. Stir the reaction mixture at 80° C. for 12 h, cool to room temperature, wash 3× with 1 N HCl, 1× with water and dry the organic layer over MgSO4. Purify by silica gel chromatography, eluting with ethyl acetate:hexane (4:1) to obtain 5.1 g of (3R, 4S)-1,4-bis(4-methoxyphenyl)-3-(3-bromoproyl)-2-azetidinone (relative stereochemistry), mp 70°-73° C., El (M+) 404; J=2.3 Hz.

Step 2) To a solution of the product of step 1 (5.1 g, 12.6 mmol) in (CH3)2SO (20 ml), add (CH3)3N(O) (2.39 g, 31.9 mmol). Heat the mixture at 60° C. for 3 h, cool to room temperature, dilute with EtOAc, and wash 3× with water. Combine the aqueous fractions and extract with EtOAc. Combine the organic fractions and concentrate. Purify the crude product by silica gel chromatography, eluting with EtOAc:hexane (1:1) to obtain 1.4 g (3R, 4S)-1,4-bis-(4-methoxyphenyl)-2-oxo-3-azetidine-propanol (relative stereochemistry), an oil; EI (M+) 339; J=2.3 Hz.

Step 3) To a solution of the product of step 2 (0.7134 0.734 g, 2.2 mmol) in THF (4 ml) at 0° C., add phenylmagnesium bromide (2.4 ml, 2.4 mmol, 1.0 M in THF) over 0.25 h. After 1 h at 0° C., add water (5 ml), separate the layers, wash the organic layer 1 × with 1N HCl, dry with MgSO4 and concentrate to an oil. Purify by silica gel chromatography, eluting with EtOAc:hexane (2:1) to obtain 0.372 g of the title compound (mix of diastereomers) as an oil. CI (M+H) 418.

Separation of diastereomers: Apply the diastereomeric mixture from step 3 to a Chiralcel OD (Chiral Technologies Corp, Pa.) chromatography column, eluting with hexane:ethanol (9:1) to obtain enantiomerically pure (>98%) diastereomers as follows:

Method 2:

Step 1) To a solution of 1,4-(S)-bis(4-methoxyphenyl)-3-(3(R)-phenylpropyl)-2-azetidinone (5.04 g, 0.013 mole) in CCl4 (20 ml) at 80° C., add NBS (2.76 g, 0.0155 mole) and benzoyl peroxide (0.24 g, 1.0 mmole) in three equal portions over 1 h. Follow the reaction by TLC (4:1 hexane:EtOAc). Cool the reaction to 22° C., add NaHSO4, separate the layers and wash the organic layer 3× with water. Concentrate the organic layer to obtain the crude product.

CI (M+H) 480; 1H in CDCl3 δ PhCH(OH)=5.05 ppm.

Step 2) Dissolve the crude product of Step 1 in CH2Cl2 (30 ml) and add 40% n-BuNOC(O)CF3 in water (30 ml). Reflux the biphasic reaction for 24 h, cool, separate the layers and wash the organic layer 6× with water. Concentrate the organic layer to dryness and immediately redissolve the residue in ethanol saturated with NH3 (10 ml). After 1 h, concentrate the reaction mixture and partially purify by silica gel chromatography. Further purify by HPLC to obtain a 1:1 mixture of compounds 4A and 4B. The mixture can be further purified on a Chiracel OD column to obtain 4A and 4B separately as characterized above.

Using the procedure described in Example 4, Method 2, with 4(S)-(4-acetoxyphenyl)-3(R)-(3-phenylpropyl)-1-(4-methoxy-phenyl)-2-azetidinone as the starting material, prepare the following compounds:

EXAMPLE 5

To a solution of the product of step 2 of Example 4 (0.230 g, 0.68 mmol) in THF (2 ml), add the reagent derived from treatment of 4-methoxymethylphenyl bromide (0.159 g, 0.736 mmol) in THF (4 ml) at −78° C. with sec-butyllithium (0.6 ml, 0.78 mol, 1.3M in hexanes), followed by CeCl3 (0.186 g, 0.75 mmol). After 4 h, extract the product and purify by chromatography in a manner similar to that described in step 3 of Example 4 to obtain 0.05 g of the title compound (mix of diastereomers) as an oil. CI (M+H) 478.

EXAMPLE 6

Step 1): To a solution of (S)-4-phenyl-2-oxazolidinone (41 g, 0.25 mol) in CH2Cl2 (20 ml), add 4-dimethylaminopyridine (2.5 g, 0.02 mol) and triethylamine (84.7 ml, 0.61 mol) and cool the reaction to 0° C. Add methyl-4-(chloroformyl)butyrate (50 9 g, 0.3 mol) as a solution in CH2Cl2 (375 ml) dropwise over 1 h, and allow the reaction to warm to 22° C. After 17 h, add water and H2SO4 (2N, 100 ml), separate the layers, and wash the organic layer sequentially with NaOH (10%). NaCI (sat'd) and water. Dry the organic layer over MgSO4 and concentrate to obtain a semicrystalline product.

Step 2): To a solution of TiCl4 (18.2 ml, 0.165 mol) in CH2 Cl2 (600 ml) at 0° C., add titanium isopropoxide (16.5 ml, 0.055 mol). After 15 min, add the product of Step 1 (49.0 9, 0.17 mol) as a solution in CH2 Cl2 (100 ml). After 5 min., add diisopropylethylamine (DIPEA) (65.2 ml, 0.37 mol) and stir at 0° C. for 1 h, cool the reaction mixture to −20° C., and add 4-benzyloxybenzylidine(4-fluoro)aniline (114.3 g, 0.37 mol) as a solid. Stir the reaction vigorously for 4 h at −20° C., add acetic acid as a solution in CH2Cl2 dropwise over 15 min, allow the reaction to warnr warm to 0° C., and add H2 SO4 (2N). Stir the reaction an additional 1 h, separate the layers, wash with water, separate and dry the organic layer. Crystallize the crude product from ethanol/water to obtain the pure intermediate.

Step 3): To a solution of the product of Step 2 (8.9 g, 14.9 mmol) in toluene (100 ml) at 50° C., add N,O-bis(trimethylsilyl)acetamide (BSA) (7.50 ml, 30.3 mmol). After 0.5 h, add solid TBAF (0.39 g, 1.5 mmol) and stir the reaction at 50° C. for an additional 3 h. Cool the reaction mixture to 22° C., add CH3OH (10 ml), wash the reaction mixture with HCl (1N), NaHCO3 (1N) and NaCI (sat'd), and dry the organic layer over MgSO4.

Step 4): To a solution of the product of Step 3 (0.94 g, 2.2 mmol) and CH3OH (3 ml), add water (1 ml) and LiOH.H2O (102 mg, 2.4 mmole). Stir the reaction at 22° C. for 1 h and add additional LiOH.H2O (54 mg, 1.3 mmole). After a total of 2 h, add HCl (1N) and EtOAc, separate the layers, dry the organic layer and concentrate in vacuo. To a solution of resultant product (0.91 g, 2.2 mmol) in CH2Cl2 at 22° C., add ClCOCOCl (0.29 ml, 3.3 mmol) and stir for 16 h. Remove the solvent in vacuo.

Step 5): To an efficiently stirred suspension of 4-fluorophenylzinc chloride (4.4 mmol) prepared from 4-fluorophenylmagnesium bromide 5 (1M in THF, 4.4 ml, 4.4 mmol) and ZnCl2 (0.6 g, 4.4 mmol) at 4° C., add tetrakis(triphenylphosphine)palladium (0.25 g, 0.21 mmol) and the product of Step 4 (0.94 g, 2.2 mmol) as a solution in THF (2 ml). Stir the reaction for 1 h at 0° C. and then for 0.5 h at 22° C. Add HCl (1N, 5 ml) and extract with EtOAc. Concentrate the organic layer to an oil and purify by silica gel chromatography to obtain 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-3(R)-(3-oxo-3-phenylpropyl)-2-azetidinone:

HRMS calc'd for C24H19F2NO3=408.1429, found 408.1411.

Step 6): To the product of Step 5 (0.95 g, 1.91 mmol) in THF (3 ml), add (R)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo-[1,2-c][1,3,2]oxazaborole (120 mg, 0.43 mmol) and cool the mixture to −20° C. After 5 min, add borohydride-dimethylsulfide complex (2M in THF: 0.85 ml, 1.7 mmol) dropwise over 0.5 h. After a total of 1.5 h, add CH3OH followed by HCl (1 N) and extract the reaction mixture with EtOAc to obtain 1-(4-fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-[4-(phenylmethoxy)phenyl]-2-azetidinone (compound 6A-1) as an oil. 1H in CDCl3 δ H3=4.68, J=2.3 Hz. CI (M+H) 500.

Use of (S)-tetra-hydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo-[1,2-c][1,3,2] oxazaborole gives the corresponding 3(R)-hydroxypropyl azetidinone (compound 6B-1). 1H in CDCl3 δ H3=4.69, J=2.3 Hz. CI (M+H) 500.

To a solution of compound 6A-1 (0.4 g, 0.8 mmol) in ethanol (2 ml), add 10% Pd/C (0.03 g) and stir the reaction under a pressure (60 psi) of H2 gas for 16 h. Filter the reaction mixture and concentrate the solvent to obtain compound 6A. Mp 164°-166° C.; CI (M+H) 410.

[α]D 25=−28.1° (c 3, CH3OH). Elemental analysis calc'd for C24H21F2NO3; C 70.41; H 5.17; N 3.42; found C 70.25; H 5.19; N 3.54.

Similarly treat compound 6B-1 to obtain compound 6B. Mp 129.5°-132.5° C.; CI (M+H) 410. Elemental analysis calc'd for C24H21F2NO3: C 70.41; H 5.17; N 3.42; found C 70.30; H 5.14; N 3.52.

Step 6′) (Alternative): To a solution of the product of Step 5 (0.14 g, 0.3 mmol) in ethanol (2 ml), add 10% Pd/C (0.03 g) and stir the reaction under a pressure (60 psi) of H2 gas for 16 h. Filter the reaction mixture and concentrate the solvent to afford a 1:1 mixture of compounds 6A and 6B.

Using appropriate starting materials and following the procedure of steps 1-6, prepare the following compounds:

EXAMPLE 7

To a solution of 7a (1.0 g, 2.1 mmol) in dioxane (10 ml), add SeO2 (1.33 g, 11.98 mmol) and water (25 ml, 14 mmol), ( 0.25 ml, 14 mmol), and heat the reaction to 100° C. After 1 h, cool the reaction to room temperature and isolate by extraction the crude product as a diastereomeric mixture (1:2) of alcohols 7b-A and 7b-B. Purify by HPLC on a Dynamax silica column to separate diastereomers 7b-A and 7b-B.

Diastereomer 7b-A (R): oil; J34=2.3 Hz, δ C H(OH)=4.86 (t); HRMS C32H29NO4 calc.: 491.2097; found: 491.2074.

Diastereomer 7b-E (S): oil; J34=2.3 Hz, δ C H(OH)=5.06 (t); HRMS C32H29NO4 calc.: 491.2097; found: 491.2117.

Step 2): To a solution of diastereomer A from step 1 (58 mg, 0.12 mmol) in EtOAc (2 ml), add 10% Pd on carbon (20 mg) and stir at 22° C. under H2 gas (14 psi) for 12 h. Filter and concentrate to obtain the title compound as a semisolid, m.p. 90°-92° C. J34=2.3 Hz, δ CH(OH)=4.1 (m); HRMS C25H25NO4 calc: 403.1783; found: 403.1792.

EXAMPLE 8

To a solution of the product of Example 4A (90 mg, 0.2 mmol) in CH2Cl2, add acetyl chloride (80 mg, 1.0 mmol) and pyridine (8 mg, 0.1 mmol) and stir at room temperature for 1 h. Add water, separate the layers and isolate the corresponding acetoxy compound, 8A. In a similar manner, treat the products of Examples 4B, 6B and 6A to obtain the following compounds 8B, 8° C. and 8D, respectively:

8A: 1,4(S)-bis(4-methoxyphenyl)-3(R)-(3(R)-acetoxy-3-phenylpropyl)-2-azetidinone. CI (M+H) 460; HRMS C28H29NO5 calc.: 459.2044; found: 459.2045.

8B: 1,4(S)-bis(4-methoxyphenyl)-3(R)-(3(S)-acetoxy-3-phenylpropyl)-2-azetidinone. CI (M+H) 460; HRMS C28H29NO5 calc.: 459.2044; found 459.2048.

8C: 4(S)-(4-acetyloxyphenyl)-3(R)-(3(R)-acetyloxi y-3-(4-fluorophenyl)propyl)-1-(4-fluorophenyl)-2-azetidinone. FAB M:S 493.4; HRMS C28H25F2NO5 calc.: 493.1695; found: 493.1701.

8D: 4(S)-(4-acetyloxyphenyl)-3(R)-(3(S)-acetyloxy-3-(4-fluorophenyl)propyl)-1-(4-fluorophenyl)-2-azetidinone. FAB MS 493.4; HRMS C28H25F2NO5 calc.: 493.1695; found: 493.1694.

Using appropriate starting materials in the procedure of Example 6, prepare 1-(4-chlorophenyl)-3(R)-(hydroxy-3. -(4-chlorophenylpropyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone. Using the procedure of Example 8, prepare the following diacetates 8E and 8F:

EXAMPLE 9

Step 1:

Add pyridinium chlorochromate (2.4 g, 11 mmoles) and CH3CO2Na (approx. 20 mg) to a solution of 1-phenyl-3-(3-phenyl-1-hydroxypropyl)-4-(4-methoxyphenyl)-2-azetidinone (2.35 g, 6.1 mmoles) in CH2Cl2. Stir at room temperature for 18 h, then add silica gel (40 g) and concentrate to dryness. Flash chromatograph the residue using EtOAc:Hex (1:4) to obtain an oil. (1.98 g, yield=85%). 1H NMR 2.85-2.95 (m, 3H), 3.15 (m, 1H), 3.80 (s, 3H), 4.10 (d, 1H, J 2.6), 5.42 (1H, d, 6.85 (dd, 2H, J 2.8), 7.05 (m, 1H), 7.2-7.35 (m, 11H).

Step 2:

To a solution of the product of Step 1 (1.78 g, 4.62 mmoles) in THF at −10° C., add NaH (115 mg, 4.8 mmoles). After 15 min, add NBS (865 mg, 4.85 mmoles) and stir for 20 min., then add 1N HCl and partition between EtOAc and brine. Separate the organic layer, dry (MgSO4) and concentrate to give an oil. Flash chromatograph the oil using EtOAc:Hex (1:10) to collect first 9a as a foamy solid (830 mg, y=39%, FAB MS 466/464, M+H), and then 9b as a colorless solid (1.1 g, y=51%, FAB MS 466/464, M+H).

Step 3a:

Add Mg(OCOCF3)2.CF3CO2H (7.3 ml of 1M solution is Et2O.) to a solution of 9a (0.68 g, 1.46 mmoles) in THF (5 ml) at −50° C. Stir the reaction 5 min., then add t-Bu—NH2-BH3 (254 mg, 2.92 mmole). After 15 min., allow the reaction to warm to 0° C. over 20 min., add 1N HCl and concentrate in vacuo. Partition the residue between EtOAc and brine. Concentrate the organic layers and dissolve the resultant oil in CH2Cl2:CH3OH (1:1) and add ethanolamine (approx 2 mmoles). After 15 min., concentrate the reaction mixture and partition the residue with EtOAc:1N HCl. Wash (brine) and dry (MgSO4) the organic layer to obtain an oil. Purify this oil by flash chromatography using EtOAc:Hex (1:4) to obtain compound 9a-1, a colorless solid, as a 4:1 mix of diastereomers. 0.52 g, y=76%, SIMS 468/466 (M+H).

Step 3b:

Using compound 9b as the starting material, use a procedure similar to Step 3a with CH2Cl2 as solvent for the preparation of 9b-1 in 80% yield as a 13:1 mixture of diastereomers (SIMS 468/466 M+H).

Step 4a:

Add a solution of 9a-1 (0.27 g, 0.58 mmoles) and AIBN (18 mg, 0.12 mmole) in toluene (40 ml) dropwise over 40 min. to a solution of (TMS)3SiH (1.0 ml) in toluene at 80° C. for 1.5 h. Cool and concentrate the reaction mixture, dissolve the residue in CH3CN and wash 3× with hexane. Concentrate the CH3CN layer to give the title compound as a racemic mixture (0.25 g). Purify this oil by HPLC using a Chiralcel OD column to obtain 3H (major) and 3J (minor).

Step 4b:

Use the procedure of Step 4a, starting with compound 9b-1 to obtain an oil. Purify this by flash chromatography using EtOAc:Hex (1:3) to collect the racemic title compound (y=70%). Purify this oil by HPLC using a Chiralcel OD column to obtain 3J (major) and 3H (minor).

EXAMPLE 10

Step 1:

Follow the procedure of Example 3, using 1-(4-fluorophenyl-4-(4-t-butyldimethylsilyloxyphenyl)-2-azetidinone to obtain 1-(4-fluorophenyl-3-(3-phenyl-1-hydroxypropyl) 4-(4-t-butyldimethylsilyl-oxyphenyl)-2-azetidinone.

Step 2:

Treat a solution of the cis-azetidinone of Step 1 (0.25 g) in CH3CN CH3 CN (21 ml) with 48% aqueous HF (2.5 ml). After 18 h, dilute the reaction mixture with cold H2O and extract with Et2O. Wash (2× H2O, dilute NaHCO3 and brine), dry (MgSO4) and concentrate the Et2O layer. Crystallize the residue from EtOAc:hexane (1:2) to obtain the title compound as colorless needles (123 mg, y=64%), mp 168°-171° C. Elemental analysis calc for C24H22O3FN: C 73.64; H 5.66; N 3.58. found C 73.32; H 5.65; N 3.68.

The following formulations exemplify some of the dosage of this invention. In each the term “active compound” designates a compound of formula I.

EXAMPLE A

Tablets
No. Ingredient mg/tablet mg/tablet
1 Active Compound 100 500
2 Lactose USP 122 113
3 Corn Starch, Food Grade, as a 10%  30  40
paste in Purified Water
4 Corn Starch, Food Grade  45  40
5 Magnesium Stearate  3  7
Total 300 700

Method of Manufacture

Mix Item Nos. 1 and 2 in suitable mixer for 10-15 minutes. Granulate the mixture with Item No. 3. Mill the damp granules through a coarse screen (e.g., ¼′, 0.63 cm) if necessary. Dry the cl damp granules. Screen the dried granules if necessary and mix with Item No. 4 and mix for 10-15 minutes. Add Item No. 5 and mix for 1-3 minutes. Compress the mixture to appropriate size and weight on a suitable tablet machine.

EXAMPLE B

Capsules
No. Ingredient mg/tablet mg/tablet
1 Active Compound 100 500
2 Lactose USP 106 123
3 Corn Starch, Food Grade  40  70
4 Magnesium Stearate NF  4  7
Total 250 700

Method of Manufacture

Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the mixture suitable two-piece hard gelatin capsules on a suitable encapsulating machine.

Representative formulations comprising a cholesterol biosynthesis inhibitor are well known in the art. It is contemplated that where the two active ingredients are administered as a single composition, the dosage forms disclosed above for substituted azetidinone compounds may readily be modified using the knowledge of one skilled in the art.

Using the test procedures described above, the following in vivo data were obtained for the exemplified compounds. Data is reported as percent change (i.e., percent reduction in cholesterol esters) versus control, therefore, negative numbers indicate a positive lipid-lowering effect.

% Reduction
Serum Cholest. Dose
Ex. # Cholest. Esters mg/kg
1A −23 0 50
1B −15 −39 50
1C 14 0 50
2 0 0 50
3A −31 −69 50
3C −60 −92 50
3D −17 −61 10
3E 0 0 10
3F −29 −77 10
3G −16 −38 10
3H −41 −86 10
3I 0 −22 10
3J 0 0 3
3K 0 0 10
3L −15 −21 10
3M 0 −22 10
4A 0 −54 5
4B −37 −89 8
4C −12.5 0 3
4D 9 0 7
4E 0 −46 3
4F −29 −95 3
5 0 −64 10
6A −59 −95 1
6A-1 −43 −93 1
6B −40 −92 3
6C 0 −48 3
6D −46 −95 10
8A 0 −44 3
8B −50 −95 3
8C −14 −37 1
8D −49 −98 1
8E −22 −66 3
8F −43 −94 1
10 −26 −77 3

Claims (13)

We claim:
1. A compound represented by the formula
or a pharmaceutically acceptable salt thereof, wherein:
Ar1 and Ar2 are independently selected from the group consisting of aryl and R4-substituted aryl;
Ar3 is aryl or R5-substituted aryl;
X, Y and Z are independently selected from the group consisting of —CH2—, —CH(lower alkyl)- and —C(dilower alkyl)-;
R and R2 are independently selected from the group consisting of —OR6, —O(CO)R6, —O(CO)OR9 and —O(CO)NR6R7;
R1 and R3 are independently selected from the group consisting of hydrogen, lower alkyl and aryl;
q is 0 or 1; r is 0 or 1; m, n and p are independently 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
R4 is 1-5 substituents independently selected from consisting of lower alkyl, —OR6, —O(CO)R6, —O(CO) OR9, —O(CH2)1-5OR6, —(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, -(lower alkylene)COOR6, —CH═CH—COOR6, —CF3, —CN, —NO2 and halogen;
R5 is 1-5 substituents independently selected from the group consisting of —OR6, —O(CO)R6, —O(CO) OR9, —O(CH2)1-5OR6, —(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, -(lower alkylene)COOR6 and —CH═CH—COOR6;
R6, R7 and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and
R9 is lower alkyl, aryl or aryl-substituted lower alkyl.
2. A compound of claim 1 wherein Ar1 is phenyl or R4-substituted phenyl, Ar2 is phenyl or R4-substituted phenyl and Ar3 is R5-substituted phenyl.
3. A compound of claim 2 wherein Ar1 is R4-substituted phenyl wherein R4 is halogen; Ar2 is R4-substituted phenyl wherein R4 is halogen or —OR6, wherein R6 is lower alkyl or hydrogen; and Ar3 R5-substituted phenyl, wherein R5 is —OR6, wherein R6 is lower alkyl or hydrogen.
4. A compound of claim 1 wherein X, Y, and Z are each —CH2—; R1 and R3 are each hydrogen; R and R2 are each —OR6, wherein R6 is hydrogen; and the sum of m, n, p, q and r is 2, 3 or 4.
5. A compound of claim 1 wherein m, n and r are each zero, q is 1 and p is 2.
6. A compound of claim 1 wherein p, q and n are each zero, r is 1 and m is 2 or 3.
7. A compound selected from the group consisting of
rel 3(R)-(2(R)-hydroxy-2-phenylethyl)-4(R)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
rel 3(R)-(2(R)-hydroxy-2-phenylethyl)-4(S)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
3(S)-(1(S)-hydroxy-3-phenylpropyl)-4(S)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
3(S)-(1(R)-hydroxy-3-phenylpropyl)-4(S)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
3(R)-(1(R)-hydroxy-3-phenylpropyl)-4(S)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
rel-3(R)-[(S)-hydroxy-(2-naphthalenyl)methyl]-4(S)-(4-methoxyphenyl)-1-phenyl)-1-phenyl-2-azetidinone;
rel-3(R)-[(R)-hydroxy-(2-naphthalenyl)methyl]-4(S)-(4-methoxyphenyl)-1-phenyl-2-azetidinone;
3(R)-(3(R)-hydroxy-3-phenylpropyl)-1,4(S)-bis-(4-methoxyphenyl-2-azetidinone;
3(R)-(3(S)-hydroxy-3-phenylpropyl)-1,4(S)-bis-(4-methoxyphenyl-2-azetidinone;
4(S)-(4-hydroxyphenyl)-3(R)-(3(R)-hydroxy-3-phenylpropyl-1-(4-methoxyphenyl)-2-azetidinone;
4(S)-(4-hydroxyphenyl)-3(R)-(3(S)-hydroxy-3-phenylpropyl-1-(4-methoxyphenyl)-2-azetidinone;
rel 3(R)-[3(RS)-hydroxy-3-[4-methoxymethoxy)-phenyl]propyl]-1,4(S)-bis-(4-methoxyphenyl)-2-azetidinone;
1-(4-fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone;
1-(4-fluorophenyl)-3(R)-[3(R)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone;
4(S)-[4-(acetyloxy)phenyl]-3(R)-(3(R)-hydroxy-3-phenylpropyl)-1-(4-methoxyphenyl)-2-azetidinone;
4(S)-[4-(acetyloxy)phenyl]-3(R)-(3(S)-hydroxy-3-phenylpropyl)-1-(4-methoxyphenyl)-2-azetidinone;
1-(4-fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-[4-(phenylmethoxy)phenyl]-2-azetidinone;
3(R)-[3(R)-acetyloxy)-3-phenylpropyl]-1,4(S)-bis-(4-methoxyphenyl)-2-azetidinone;
3(R)-[3(S)-acetyloxy)-3-phenylpropyl]-1,4(S)-bis-(4-methoxyphenyl)-2-azetidinone;
3(R)-[3(R)-(acetyloxy)-3-(4-fluorophenyl)propyl]-4(S)-[4-(acetyloxy)phenyl]-1-(4-fluorophenyl)-2-azetidinone;
3(R)-[3(S)-(acetyloxy)-3-(4-fluorophenyl)propyl]-4(S)-[4-(acetyloxy)phenyl]-1-(4-fluorophenyl)-2-azetidinone;
3(R)-[3(R)-(acetyloxy)-3-(4-chlorophenyl)propyl]-4(S)-[4-(acetyloxy)phenyl]-1-(4-chlorophenyl)-2-azetidinone;
3(R)-[3(S)-(acetyloxy)-3-(4-chlorophenyl)propyl]-4(S)-[4-(acetyloxy)phenyl]-1-(4-chlorophenyl)-2-azetidinone; and
rel 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-3(1R)-(1(R)-hydroxy-3-phenylpropyl)-2-azetidinone.
8. A pharmaceutical composition for the treatment or prevention of athersclerosis , atherosclerosis or for the reduction of plasma cholesterol levels, comprising an effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
9. A method of treating or preventing atherosclerosis or reducing plasma cholesterol levels comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 1.
10. A compound comprising 1-( 4 -fluorophenyl)- 3 (R)-[3 (S)-( 4 -fluorophenyl)- 3 -hydroxypropyl)]- 4 (S)- 4 -(hydroxyphenyl)- 2 -azetidinone or a pharmaceutically acceptable salt thereof.
11. A compound represented by the formula:
12. A pharmaceutical composition for the treatment or prevention of atherosclerosis, or for the reduction of plasma cholesterol levels, comprising an effective amount of a compound according to claims 10 or 11 in a pharmaceutically acceptable carrier.
13. A method of treating or preventing atherosclerosis or reducing plasma cholesterol levels comprising administering to a mammal in need of such treatment an effective amount of a compound according to claims 10 or 11.
US09594996 1993-09-21 2000-06-15 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents Expired - Lifetime USRE37721E1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10244093 true 1993-09-21 1993-09-21
US08257593 US5631365A (en) 1993-09-21 1994-06-09 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US08617751 US5767115A (en) 1993-09-21 1996-03-18 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US09594996 USRE37721E1 (en) 1993-09-21 2000-06-15 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12797341 USRE42461E1 (en) 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US09594996 USRE37721E1 (en) 1993-09-21 2000-06-15 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08617751 Reissue US5767115A (en) 1993-09-21 1996-03-18 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12797341 Reissue USRE42461E1 (en) 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Publications (1)

Publication Number Publication Date
USRE37721E1 true USRE37721E1 (en) 2002-05-28

Family

ID=26799377

Family Applications (5)

Application Number Title Priority Date Filing Date
US08257593 Expired - Lifetime US5631365A (en) 1993-09-21 1994-06-09 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US12797341 Expired - Lifetime USRE42461E1 (en) 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US08617751 Expired - Lifetime US5767115A (en) 1993-09-21 1996-03-18 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US08953825 Expired - Lifetime US5846966A (en) 1993-09-21 1997-10-14 Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
US09594996 Expired - Lifetime USRE37721E1 (en) 1993-09-21 2000-06-15 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US08257593 Expired - Lifetime US5631365A (en) 1993-09-21 1994-06-09 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US12797341 Expired - Lifetime USRE42461E1 (en) 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US08617751 Expired - Lifetime US5767115A (en) 1993-09-21 1996-03-18 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US08953825 Expired - Lifetime US5846966A (en) 1993-09-21 1997-10-14 Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors

Country Status (14)

Country Link
US (5) US5631365A (en)
JP (1) JP2803908B2 (en)
KR (1) KR186853B1 (en)
CN (1) CN1050830C (en)
CA (1) CA2172149C (en)
DE (4) DE10399001I2 (en)
DK (1) DK0720599T3 (en)
EP (1) EP0720599B1 (en)
ES (1) ES2132432T3 (en)
FI (1) FI110321B (en)
LU (4) LU91050I2 (en)
NL (2) NL300132I2 (en)
RU (1) RU2138480C1 (en)
WO (1) WO1995008532A1 (en)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105028A1 (en) * 2000-12-20 2003-06-05 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6627757B2 (en) 2001-03-28 2003-09-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
US20040116510A1 (en) * 2002-03-05 2004-06-17 Nichtberger Steven A. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
US20040126423A1 (en) * 2002-07-26 2004-07-01 Moore William D. Pharmaceutical formulation
US20040161838A1 (en) * 2002-07-19 2004-08-19 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040167150A1 (en) * 2000-10-30 2004-08-26 Harris Alan G. Treatment methods
WO2005062824A2 (en) 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
US20050209165A1 (en) * 2003-11-10 2005-09-22 Eduardo Martinez 4-Biarylyl-1-phenylazetidin-2-ones
US20050239766A1 (en) * 2002-07-05 2005-10-27 Astrazeneca Ab Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
US20060161994A1 (en) * 2004-12-15 2006-07-20 Schering Corporation Functional assays for cholesterol absorption inhibitors
US20070015807A1 (en) * 2005-06-20 2007-01-18 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
US20070078098A1 (en) * 2005-10-05 2007-04-05 Devita Robert J Anti-hypercholesterolemic compounds
US20070142304A1 (en) * 2003-12-23 2007-06-21 Susanne Alenfalk Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity
US20070161578A1 (en) * 2005-12-21 2007-07-12 Hwa Joyce J Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
US20070259845A1 (en) * 2005-09-08 2007-11-08 Kansal Vinod K Processes for the preparation of (3R,4S)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
US20080064676A1 (en) * 2003-12-23 2008-03-13 Astrazeneca Ab Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20080200669A1 (en) * 2005-05-11 2008-08-21 Microbia, Inc. Processes For Production of Phenolic 4-Biphenylylazetidin-2-Ones
US20080287663A1 (en) * 2005-05-06 2008-11-20 Microbia, Inc. Process For Production Of 4-Biphenylyazetidin-2-Ones
US20090047716A1 (en) * 2007-06-07 2009-02-19 Nurit Perlman Reduction processes for the preparation of ezetimibe
US20090069285A1 (en) * 2006-04-27 2009-03-12 Astrazeneca Ab Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitor Activity
US20090099355A1 (en) * 2005-05-25 2009-04-16 Microbia, Inc. Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids
US20090098128A1 (en) * 2006-02-24 2009-04-16 Altmann Scott W NPC1L1 orthologues
US20090105208A1 (en) * 2007-06-28 2009-04-23 Schering Corporation Substituted Piperazines as CB1 Antagonists
US20090292135A1 (en) * 2005-05-09 2009-11-26 Ironwood Pharmaceuticals, Inc. Organometal benzenephosphonate coupling agents
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
US20100004184A1 (en) * 2005-06-15 2010-01-07 Robert J De Vita Anti-hypercholesterolemic compounds
US20100009461A1 (en) * 2004-01-16 2010-01-14 Merck & Co., Inc. Npcil1 (Npc3) And Methods Of Identifying Ligands Thereof
US20100048529A1 (en) * 2005-06-22 2010-02-25 Astrazeneca Ab New 2-Azetidinone Derivatives Useful In The Treatment Of Hyperlipidaemic Conditions
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
US20100137273A1 (en) * 2005-06-22 2010-06-03 Astrazeneca Ab Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions
US7732413B2 (en) 2003-03-07 2010-06-08 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7741289B2 (en) 2003-03-07 2010-06-22 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US20100204195A1 (en) * 2007-07-27 2010-08-12 Cipla Limited Pharmaceutical Compositions and Process for Making Them
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
WO2011002424A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
WO2011017907A1 (en) 2009-08-11 2011-02-17 浙江海正药业股份有限公司 Azetidinone compounds and medical use thereof
US7897601B2 (en) 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
EP2322548A1 (en) 2003-07-17 2011-05-18 Schering Corporation NPC1L1 (NPC) and methods of use thereof
WO2012173504A2 (en) 2011-06-15 2012-12-20 Instytut Chemii Organicznej Polskiej Akademii Nauk Method for synthesis of the substituted azetidinones and intermediates for their synthesis
US9040688B2 (en) 2009-03-31 2015-05-26 Lupin Limited Intermediates in the preparation of 1,4-diphenyl azetidinone
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
JPH10501811A (en) * 1994-06-20 1998-02-17 シェーリング コーポレイション Useful as hypocholesterolemic agents substituted azetidinone compound
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
WO1997012053A1 (en) * 1995-09-27 1997-04-03 Schering Corporation Stereoselective microbial reduction process
US5843938A (en) * 1995-10-03 1998-12-01 Beiersdorf-Lilly Gmbh Treatment of atherosclerosis
EP0766962A3 (en) * 1995-10-03 2000-05-10 Beiersdorf-Lilly GmbH Treatment of atherosclerosis
CA2235943C (en) * 1995-10-31 2002-10-01 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
WO1997016424A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
ES2248840T3 (en) 1996-02-23 2006-03-16 Eli Lilly And Company Antagonists of non-peptidyl vasopressin V1a.
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2762336B1 (en) * 1997-04-21 1999-06-11 Francois Trantoul Process for manufacturing a film unreproducible pattern by optical scanning for the protection of materials
US6133001A (en) * 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
EP1137634B1 (en) * 1998-12-07 2005-06-15 Schering Corporation Process for the synthesis of azetidinones
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
CN1338944A (en) 1998-12-23 2002-03-06 G.D.瑟尔有限公司 Cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
DK1140184T3 (en) * 1998-12-23 2003-09-29 Searle Llc Combinations of cholesterylestertransferproteinhæmmere and nicotinic acid derivatives for cardiovascular indications
US6562860B1 (en) 1998-12-23 2003-05-13 G. D. Searle & Co. Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
DK1140188T3 (en) 1998-12-23 2003-09-29 Searle Llc Combinations of ileal bile acid transport inhibitors, and cholesteryl esters tranferproteinhæmmere for cardiovascular indications
CA2356515A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications
JP2002533409A (en) 1998-12-23 2002-10-08 ジー.ディー.サール エルエルシー Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestrants for application to the cardiovascular
CA2356607A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
JP3679715B2 (en) 1999-04-05 2005-08-03 シェーリング コーポレイションSchering Corporation 1- (4-fluorophenyl) -3 (r) - [3 (s) - hydroxy-3- (4-fluorophenyl) propyl)] - 4 (s) - (4-hydroxyphenyl) -2-azetidinone stereoselective microbial reduction for the preparation
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
JP2003528830A (en) 2000-03-10 2003-09-30 ファルマシア・コーポレーション Method for producing tetrahydrobenzo Chie pin acids
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
EP1510521A1 (en) * 2000-12-20 2005-03-02 Schering Corporation Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
EP1593670B1 (en) * 2000-12-20 2007-08-08 Schering Corporation Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic agents
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
DE60129863T2 (en) 2000-12-20 2008-04-30 Schering Corp. Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic drug
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
KR20030061462A (en) 2000-12-21 2003-07-18 아벤티스 파마 도이칠란트 게엠베하 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
DE50111751D1 (en) * 2000-12-21 2007-02-08 Sanofi Aventis Deutschland New diphenzylazetidinone, process for their preparation, these compounds containing drug and its use for treatment of lipid metabolic disorders
EP1385548B1 (en) * 2001-01-26 2007-05-23 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
KR100596257B1 (en) * 2001-01-26 2006-07-03 쉐링 코포레이션 A composition comprising sterol absorption inhibitor, and a composition and a therapeutic combinations comprising peroxisome proliferator-activated receptorPPAR activator and sterol absorption inhibitor
EP1671650A1 (en) * 2001-01-26 2006-06-21 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
KR100820983B1 (en) * 2001-01-26 2004-03-26 쉐링 코포레이션 A pharmaceutical composition comprising substituted azetidinone compounds
CA2434033A1 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
CA2438961C (en) * 2001-02-23 2010-02-16 Kotobuki Pharmaceutical Co., Ltd. Beta-lactam compounds, manufacturing methods of the compounds and serum hypocholesterolemic agents containing the compounds
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
DE60216275T2 (en) * 2001-05-25 2007-06-21 Schering Corp. Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
EP1859796A3 (en) * 2001-09-21 2008-07-02 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
EP1429756B1 (en) * 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
JP2005518347A (en) * 2001-11-02 2005-06-23 ジー.ディー. サール エルエルシー Apical sodium co-dependent bile acid transport (ASBT) and novel mono- and di-fluorinated benzothiepine compounds as inhibitors of taurocholate uptake
US20030181520A1 (en) * 2001-11-09 2003-09-25 Mitchell Glass Methods of reversing and preventing cardiovascular pathologies
US7094801B2 (en) * 2001-12-19 2006-08-22 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
WO2003053359A3 (en) 2001-12-19 2004-04-15 Atherogenics Inc 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
FR2833842B1 (en) 2001-12-21 2004-02-13 Aventis Pharma Sa Pharmaceutical compositions based derivatives of azetidine
CA2471639A1 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
EP1480689A1 (en) * 2002-02-28 2004-12-01 Eli Lilly And Company Method of treating atherosclerosis and hypercholesterolemia
DE10227508A1 (en) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Acid group-substituted Diphenylazetidinones, process for their production, medicaments containing these compounds and their use
JP4579681B2 (en) * 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Useful substituents heterocyclo derivatives and methods as antidiabetic agents and antiobesity agents
US6933292B2 (en) * 2002-07-30 2005-08-23 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
US20040181075A1 (en) * 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
EP1606287B1 (en) * 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004099132A3 (en) * 2003-05-05 2005-03-24 Ram Chander Aryan Process for the preparation of trans-isomers of diphenylazetidinone derivatives
EP1624871B1 (en) 2003-05-15 2009-07-15 Merck & Co., Inc. (a New Jersey corp.) Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions
CA2753318A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc Combination therapy for the treatment of dyslipidemia
EP1651231A4 (en) * 2003-07-24 2009-04-01 Merck & Co Inc Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
WO2005009955A1 (en) * 2003-07-31 2005-02-03 Hetero Drugs Limited Ezetimibe polymorphs
EP1522541A1 (en) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
WO2005042692A3 (en) * 2003-10-31 2005-09-09 Forbes Medi Tech Inc A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
CA2544309A1 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1687287A1 (en) * 2003-11-24 2006-08-09 Hetero Drugs Limited A novel process for ezetimibe intermediate
CA2558766A1 (en) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
DE502005001841D1 (en) * 2004-05-21 2007-12-13 Sanofi Aventis Deutschland A process for the preparation of 1,4-diphenylazetidinone derivatives
CA2569124C (en) 2004-06-07 2013-04-23 Merck & Co., Inc. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006004903A3 (en) * 2004-06-28 2006-05-04 Atherogenics Inc 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
WO2006026273A3 (en) * 2004-08-25 2006-09-08 Merck & Co Inc Method of treating atherosclerosis, dyslipidemias and related conditions
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
CA2578290A1 (en) * 2004-09-09 2006-03-16 Novartis Ag Combination of organic compounds
JP2008514718A (en) * 2004-09-29 2008-05-08 シェーリング コーポレイションSchering Corporation Combinations of substituents Azechidonon and cb1 antagonists
EP1865947A1 (en) 2005-04-04 2007-12-19 Pontificia Universidad Catolica de Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US8013150B2 (en) * 2005-06-22 2011-09-06 Msn Laboratories Ltd. Process for the preparation of ezetimibe
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
KR20080059233A (en) 2005-10-21 2008-06-26 노파르티스 아게 Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
CA2627599A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
DK1963260T3 (en) * 2005-12-20 2011-01-17 Richter Gedeon Nyrt A process for the preparation of ezetimibe and intermediates used therefore
DE602006009845D1 (en) * 2005-12-22 2009-11-26 Medichem Sa A process for the preparation of intermediates for the preparation of ezetimibe
US7956182B2 (en) * 2006-02-16 2011-06-07 Kotobuki Pharmaceutical Co., Ltd. Process for preparing optically active alcohols
CA2644905A1 (en) * 2006-03-06 2007-09-13 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
US20080032964A1 (en) * 2006-04-10 2008-02-07 Kansal Vinod K Process for the synthesis of azetidinone
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
CN101494980A (en) * 2006-07-14 2009-07-29 兰贝克赛实验室有限公司 Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
EP1937636A1 (en) * 2006-08-29 2008-07-02 Teva Pharmaceutical Industries Ltd. Processes for the purification of (3r,4s)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-(4-fluorophenyl)-3-oxopropyl¨azetidin-2-one
WO2008033464A3 (en) * 2006-09-15 2008-05-15 Robert G Aslanian Azetidinone derivatives for the treatment of disorders of the lipid metabolism
CA2663503A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
JP2010503672A (en) * 2006-09-15 2010-02-04 シェーリング コーポレイションSchering Corporation Spirocyclic Azetidinone Derivatives for treating lipid metabolism disorders, pain, diabetes mellitus, and other disorders
WO2008033456A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
CN101541805A (en) 2006-09-15 2009-09-23 先灵公司 Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
CN100564357C (en) 2006-10-20 2009-12-02 浙江天宇药业有限公司 Azacyclo butanone derivative and its synthesis process
WO2008085300A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Anti-hypercholesterolemic compounds
EP1939174A1 (en) * 2006-12-21 2008-07-02 LEK Pharmaceuticals D.D. Inclusion complex of ezetimibe and a cyclodextrin and processes in the preparation thereof
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
CN102285906B (en) 2007-01-24 2014-11-19 克尔克公司 Process for preparation of ezetimibe and derivatives thereof
WO2008096372A3 (en) * 2007-02-06 2010-06-24 Ind-Swift Laboratories Limited Process for preparing highly pure ezetimibe using novel intermediates
WO2008104875A1 (en) * 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
EP2133347A4 (en) 2007-03-06 2010-03-17 Teijin Pharma Ltd 1-biarylazetidinone derivatives
WO2008112166A3 (en) 2007-03-09 2008-10-30 Indigene Pharmaceuticals Inc Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2008123953A1 (en) * 2007-04-02 2008-10-16 Merck & Co., Inc. Anti-hypercholesterolemic compound
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
US20080318920A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched ezetimibe
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
WO2009024889A3 (en) 2007-08-21 2009-07-09 Vinod Arora Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2009027785A3 (en) * 2007-08-30 2009-09-17 Pfizer Products Inc. 1, 3-oxazole derivatives as cetp inhibitors
US20090093627A1 (en) * 2007-08-30 2009-04-09 Lorand Szabo Process for preparing intermediates of ezetimibe by microbial reduction
DE102007063671A1 (en) * 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh , Pharmaceuticals novel crystalline Diphenylazetidinonhydrate containing these compounds and their use
EP2217214B1 (en) * 2007-12-10 2017-07-19 ratiopharm GmbH Pharmaceutical formulation comprising ezetimibe
WO2009106021A1 (en) * 2008-02-25 2009-09-03 Zentiva, K.S. Intermediates for the preparation of (3r, 4s) -1- (4-fluorophenyl) -3- [ (3s) -3- (4-fluorophenyl) -3-hydroxypropyl) ] -4- (4-hydroxyphenyl) -2-azetidinone
EP2128133A1 (en) 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetimibe process and composition
JP2011521992A (en) * 2008-06-06 2011-07-28 ニコックス エス エイ Atorvastatin 4- (nitroxy) a composition comprising a butyl ester and lipid lowering agent
EP2329014B1 (en) 2008-08-29 2014-10-22 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
EP2204170A1 (en) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
EP2229938B9 (en) 2009-03-13 2012-04-25 Sanovel Ilac Sanayi ve Ticaret A.S. Ezetimibe compositions
WO2011002422A3 (en) 2009-07-02 2011-04-28 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
EP2448919A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
ES2575560T3 (en) 2009-08-19 2016-06-29 Codexis, Inc. Ketoreductase polypeptides to prepare phenylephrine
US9181364B2 (en) 2010-02-24 2015-11-10 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants
CN102858347B (en) 2010-02-24 2016-11-02 瑞立普萨公司 As bile acid sequestrants poly imidazole
GB201216820D0 (en) 2010-02-24 2012-11-07 Relypsa Inc Amine polymers for use as bile acid sequestrants
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
EP2566497B1 (en) 2010-05-04 2015-07-29 Codexis, Inc. Biocatalysts for ezetimibe synthesis
ES2372460B1 (en) 2010-07-09 2012-11-16 Moehs Ibérica S.L. New method for the preparation of ezetimibe.
CA2815749A1 (en) 2010-11-08 2012-05-18 Albireo Ab Ibat inhibitors for the treatment of liver diseases
EP2637646B1 (en) 2010-11-08 2016-05-11 Albireo AB A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
WO2012076030A1 (en) 2010-12-10 2012-06-14 Pharmathen S.A. Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp Methods for treating lysosomal acid lipase deficiency
US8455474B2 (en) 2011-03-04 2013-06-04 Mackay Memorial Hospital Method for treating tuberculosis
WO2012155932A1 (en) 2011-05-17 2012-11-22 Pharmathen S.A. Improved process for the preparation of ezetimibe
CN102675177A (en) * 2011-06-28 2012-09-19 常州制药厂有限公司 Preparation methods of blood fat lowering medicament and key intermediates of blood fat lowering medicament
CN102952055A (en) * 2011-08-16 2013-03-06 凯瑞斯德生化(苏州)有限公司 Preparation method of ezetimibe and its intermediate
CN103204795B (en) * 2012-01-11 2016-12-14 重庆华邦胜凯制药有限公司 Preparing azetidinones one chiral compound
CN103570574B (en) 2012-07-20 2016-04-13 中国科学院上海有机化学研究所 One kind of ezetimibe ezetimibe synthesis and the intermediates used in the process
CN103102297A (en) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 Synthesis method of novel atorvastatin
US20150320724A1 (en) 2012-12-10 2015-11-12 Merck Sharp & Dohme Corp. Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
CN103864708A (en) * 2012-12-12 2014-06-18 天津市医药集团技术发展有限公司 Preparation method of ezetimibe intermediate
WO2015039675A1 (en) 2013-09-23 2015-03-26 Pharmathen S.A. Novel process for the preparation of ezetimibe intermediates
EP3065736A4 (en) 2013-11-04 2017-03-15 Merck Sharp & Dohme Glucagon receptor antagonist compounds, compositions thereof, and methods of use
US20160355473A1 (en) 2013-12-18 2016-12-08 Rudjer Boskovic Institute Beta-lactam cholesterol absorption inhibitors
CN103739537B (en) * 2013-12-24 2015-05-20 连云港恒运医药科技有限公司 New synthesis method of ezetimibe
CN103755616A (en) * 2013-12-31 2014-04-30 北京万全德众医药生物技术有限公司 Method for preparing ezetimibe isomer
US20170252352A1 (en) 2014-05-30 2017-09-07 Pfizer Inc. Methods of use and combinations
CN105294426A (en) * 2014-06-09 2016-02-03 浙江海正药业股份有限公司 Preparation method for azacyclobutanone compound and intermediate of azacyclobutanone compound
CN104447474A (en) * 2014-11-11 2015-03-25 武汉武药科技有限公司 Synthetic method of ezetimibe isomer
CN104387308A (en) * 2014-11-18 2015-03-04 武汉福星生物药业有限公司 Method for preparing high-purity ezetimibe by controlling generation of EZ-zanOH impurity
CN104513187B (en) * 2015-01-09 2017-05-31 安润医药科技(苏州)有限公司 By synthetic methods and intermediates ezetimibe

Citations (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2046823A1 (en) 1970-09-23 1972-03-30
US4144232A (en) 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
US4375475A (en) 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4443372A (en) 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4500456A (en) 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4576749A (en) 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
EP0199630A1 (en) 1985-04-10 1986-10-29 Merck & Co., Inc. Substituted azetidinones, pharmaceutical compositions containing them, and their use for the manufacture of anti-inflammatory and antidegenerative medicaments
US4620867A (en) 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
US4633017A (en) 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4675399A (en) 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
WO1987004429A1 (en) 1986-01-23 1987-07-30 The Upjohn Company Antimicrobial n-acyl-2-azetidinones
EP0264231A1 (en) 1986-10-17 1988-04-20 Taisho Pharmaceutical Co. Ltd Azetidinone derivatives
US4784734A (en) 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4794108A (en) 1984-04-24 1988-12-27 Takeda Chemical Industries, Ltd. 1-carboxymethoxy acetidinones and their production
US4834846A (en) 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
EP0333268A1 (en) 1988-03-18 1989-09-20 Merck & Co., Inc. Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
EP0337549A1 (en) 1988-04-11 1989-10-18 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
US4876365A (en) 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
EP0365364A2 (en) 1988-10-20 1990-04-25 Taisho Pharmaceutical Co. Ltd 2-Azetidinone derivatives
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5030628A (en) 1988-12-19 1991-07-09 Scientifique N-aryl-azetidinones, their preparation process and their use as elastase inhibitors
EP0462667A2 (en) 1990-06-20 1991-12-27 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5099034A (en) 1989-06-30 1992-03-24 Shionogi & Co., Ltd. Phospholipase a2 inhibitor
EP0481671A1 (en) 1990-10-15 1992-04-22 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0524595A1 (en) 1991-07-23 1993-01-27 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5229381A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
WO1994017038A1 (en) 1993-01-21 1994-08-04 Schering Corporation Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5350868A (en) 1991-09-27 1994-09-27 Ube Industries, Ltd. ω-hydroxy-(ω-3)-ketonitrile and method for preparing ω-hydroxyaliphatic acid
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
US5661145A (en) 1992-12-23 1997-08-26 Schering Corporation Combination of a cholesterol biosynthesis inhibitor and a β-lactam cholesterol absorption inhibitor
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5688990A (en) 1994-03-25 1997-11-18 Shankar; Bandarpalle B. Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5728827A (en) 1993-07-09 1998-03-17 Schering Corporation Process for the synthesis of azetidinones
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5817806A (en) 1994-03-26 1998-10-06 Glaxo Wellcome Spa Process for the preparation of cyclohexyl-azetidinones
US5847115A (en) 1992-11-13 1998-12-08 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
US5856473A (en) * 1995-11-02 1999-01-05 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(R)-(3(S)-hydroxy-3-( phenyl or 4-fluorophenyl!)-propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1063108A (en) 1973-12-28 1979-09-25 Fujisawa, Pharmaceutical Co. Azetidinone derivatives and process for preparation thereof
CA1173837A (en) 1981-03-09 1984-09-04 Theodore Goodson, Jr. 4-fluoroazetidinones
CA1267415A (en) 1983-02-02 1990-04-03 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
US4565654A (en) 1983-03-28 1986-01-21 University Of Notre Dame Du Lac N-Acyloxy monocyclic β-lactams
JPH0572910B2 (en) 1984-02-15 1993-10-13 Schering Plough Corp
US4581170A (en) 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
CA1268780A (en) 1984-08-03 1990-05-08 Richard H. Mueller N-hydroxyl protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
USRE36481E (en) 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4816477A (en) 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US4806564A (en) 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JPH0645656B2 (en) 1988-06-16 1994-06-15 出光石油化学株式会社 Styrene copolymer and a method of manufacturing
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
WO1992018462A1 (en) 1991-04-12 1992-10-29 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
US5124337A (en) 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
GB9205019D0 (en) 1991-06-18 1992-04-22 Marchbanks Roger M Metapolites of 9-amino-1,2,3,4-tetrahydroacridine and related compounds that are not liver toxic
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
CA2114007C (en) 1991-07-23 2005-12-20 Duane A. Burnett Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
US5321031A (en) 1992-09-23 1994-06-14 Schering Corporation 1,2-disubstituted ethyl amides as inhibitors of ACAT
WO1994017036A1 (en) 1993-01-22 1994-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) S-lipophilic aliphatic carbonyl [n-mercaptoacyl-(amino acid or peptide)] compounds as antihypertensive agents
JPH08507068A (en) 1993-02-26 1996-07-30 シェリング・コーポレーション 2-benzyl - Polycyclic Guanine Derivatives and methods for their preparation
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5576470A (en) 1994-08-29 1996-11-19 Henkel Corporation Polyol esters of ether carboxylic acids and fiber finishing methods
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
EP0855396A1 (en) 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
US6372756B1 (en) 1998-02-20 2002-04-16 Avmax, Inc. Epimorphian compound and its use
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
CN1209353C (en) 2000-04-07 2005-07-06 辉瑞产品公司 Estrogen agonist/antagonist metabolites
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents

Patent Citations (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2046823A1 (en) 1970-09-23 1972-03-30
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4144232A (en) 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
US4375475A (en) 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4500456A (en) 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4443372A (en) 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4479900A (en) 1982-06-23 1984-10-30 Chevron Research Company 1-Carbalkoxyalkyl-3-aryloxy-4-(2'-carboxyphenyl)-azetidin-2-ones
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
US4675399A (en) 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
US4576749A (en) 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US5229381A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US4680391A (en) 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4794108A (en) 1984-04-24 1988-12-27 Takeda Chemical Industries, Ltd. 1-carboxymethoxy acetidinones and their production
US4633017A (en) 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4620867A (en) 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
EP0199630A1 (en) 1985-04-10 1986-10-29 Merck & Co., Inc. Substituted azetidinones, pharmaceutical compositions containing them, and their use for the manufacture of anti-inflammatory and antidegenerative medicaments
WO1987004429A1 (en) 1986-01-23 1987-07-30 The Upjohn Company Antimicrobial n-acyl-2-azetidinones
US4803266A (en) 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
EP0264231A1 (en) 1986-10-17 1988-04-20 Taisho Pharmaceutical Co. Ltd Azetidinone derivatives
US4834846A (en) 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
EP0333268A1 (en) 1988-03-18 1989-09-20 Merck & Co., Inc. Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
EP0337549A1 (en) 1988-04-11 1989-10-18 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0365364A2 (en) 1988-10-20 1990-04-25 Taisho Pharmaceutical Co. Ltd 2-Azetidinone derivatives
US4876365A (en) 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US5030628A (en) 1988-12-19 1991-07-09 Scientifique N-aryl-azetidinones, their preparation process and their use as elastase inhibitors
US5099034A (en) 1989-06-30 1992-03-24 Shionogi & Co., Ltd. Phospholipase a2 inhibitor
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
EP0415487A2 (en) 1989-08-31 1991-03-06 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
EP0462667A2 (en) 1990-06-20 1991-12-27 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
EP0481671A1 (en) 1990-10-15 1992-04-22 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993002048A1 (en) 1991-07-23 1993-02-04 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5306817A (en) 1991-07-23 1994-04-26 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
EP0524595A1 (en) 1991-07-23 1993-01-27 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5350868A (en) 1991-09-27 1994-09-27 Ube Industries, Ltd. ω-hydroxy-(ω-3)-ketonitrile and method for preparing ω-hydroxyaliphatic acid
US5847115A (en) 1992-11-13 1998-12-08 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
US5661145A (en) 1992-12-23 1997-08-26 Schering Corporation Combination of a cholesterol biosynthesis inhibitor and a β-lactam cholesterol absorption inhibitor
WO1994017038A1 (en) 1993-01-21 1994-08-04 Schering Corporation Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
US5728827A (en) 1993-07-09 1998-03-17 Schering Corporation Process for the synthesis of azetidinones
US5688990A (en) 1994-03-25 1997-11-18 Shankar; Bandarpalle B. Substituted azetidinone compounds useful as hypocholesterolemic agents
US5817806A (en) 1994-03-26 1998-10-06 Glaxo Wellcome Spa Process for the preparation of cyclohexyl-azetidinones
US5856473A (en) * 1995-11-02 1999-01-05 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(R)-(3(S)-hydroxy-3-( phenyl or 4-fluorophenyl!)-propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
B. Ram et al., 1990, "Potential hypolipidemic agents:Part V†-Synthesis biological activity of new ethyl 4-(2-oxoazetidin-4-yl)phenoxyalkanoates‡" Indian Journal of Chemistry 29B:1134-1137.
B. Ram et al., 1990, "Potential hypolipidemic agents:Part Vdagger-Synthesis biological activity of new ethyl 4-(2-oxoazetidin-4-yl)phenoxyalkanoates‡" Indian Journal of Chemistry 29B:1134-1137.
Baxter, A., 1992, "Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo," The Journal of Biological Chemistry 267:11705-11708.
Burrier, R.E. et al., 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", Biochemical Pharmacology 47:1545-1551.
Burrier, R.E. et al., 1994, "The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibition on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", The Journal of Pharmacology and Experimental Therapeutics 272:156-163.
C. Allain et al., 1974, "Enzymatic Determination of Total Serum Cholesterol" Clinical Chemical, 20:470-475.
Clader, J.W. et al., 1995, "Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Vivo Activity" Journal of Medicinal Chemistry 38:1600-1607.
D. Roger Illingworth, 1988, "An Overview of Lipid-Lower Drugs" Drugs 36:63:71.
G. George et al., 1985 "3-(1′-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines" Tetrahedron Letters, vol. 26, No. 33 pp. 3903-3906.
G. George et al., 1985 "3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines" Tetrahedron Letters, vol. 26, No. 33 pp. 3903-3906.
H. Otto et al., 1983, "Darstellung und Stereochemie von 3-(alpha-Hydroxybenzyl)-1,4-diphenyl-2-azetidononen", Liebigs Ann. Chem. 1152-1161.
H. Otto et al., 1983, "Darstellung und Stereochemie von 3-(α-Hydroxybenzyl)-1,4-diphenyl-2-azetidononen", Liebigs Ann. Chem. 1152-1161.
Hart et al., 1985 "An Enantioselective Approach to Carbapenen Antibodies: Formal Synthesis of (+)-Thienamycin" Tetrahedron Letters, vol. 26, No. 45 pp. 5493-5496.
Harwood, H. James, 1993, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin beta-tigogenin cellobioside (CP-88818;tiqueside)1" Journal of Lipid Research 34:377-395.
Harwood, H. James, 1993, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β-tigogenin cellobioside (CP-88818;tiqueside)1" Journal of Lipid Research 34:377-395.
Horie, M. et al. 1991, "Hypolipidemic effects of NB-598 in dogs" Atherosclerosis 88:183-192.
Joseph L. Witztum, M.D., 1989, "CUrrent Approaches to Drug Therapy for the Hyercholesterolemic Patient" Circulation 80:1101-1114.
M. Hoekman et al., 1982, "Synthesis of Homologues of 4,5-Dihydroxy- and 4-Hydroxy-5-oxohexanoic Aciddelta-Lactones", J. Agric. Food Chem., 30:920-924.
M. Hoekman et al., 1982, "Synthesis of Homologues of 4,5-Dihydroxy- and 4-Hydroxy-5-oxohexanoic Acidδ-Lactones", J. Agric. Food Chem., 30:920-924.
Nobuki, O. et al. "Stereoselective syntheses of beta-lactam derivatives by ultrasound promoted Reformatskii reaction" Chemical Abstracts No. 106, vol. 17, Apr. 27, 1977 abstract 138174y.
Nobuki, O. et al. "Stereoselective syntheses of β-lactam derivatives by ultrasound promoted Reformatskii reaction" Chemical Abstracts No. 106, vol. 17, Apr. 27, 1977 abstract 138174y.
Otto et al., Stereochemistry of dehydration and halogenation of alphaR* and alphaS* isomeric 3-(alpha-hydroxybenzyl)-1,4-diphenyl=2-azetidinones, Chemical Abstracts No. 19, vol. 99, Nov. 7 1983 abstract 158083h.
Otto et al., Stereochemistry of dehydration and halogenation of αR* and αS* isomeric 3-(α-hydroxybenzyl)-1,4-diphenyl═2-azetidinones, Chemical Abstracts No. 19, vol. 99, Nov. 7 1983 abstract 158083h.
Panfil. I. et al., 1986, "Synthesis of beta-Lactams from alpha, beta-Unsaturated Sugar delta-Lactones" Heterocycles 24:1609-1617.
Panfil. I. et al., 1986, "Synthesis of β-Lactams from α, β-Unsaturated Sugar δ-Lactones" Heterocycles 24:1609-1617.
R. Mayrhofer et al. 1980, "Simple Preparation of 3-Benzylidene-2-azetilidinones" Synthesis, 247-248.
Salisbury, B. et al., 1995, "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" Atherosclerosis 115:45-63.
Schnitzer-Polokoff, R. et al. 1991, "Effects of Acyl-CoA:Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters" Comp. Biochem. Physiol. 99A:665-670.
Simova, E. "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", Chemical Abstracts No. 15, vol. 86, Apr. 11, 1977, Abstract 106130h.
Summary Factfile, May 1992, "Anti-Atherosclerotic Agents" Current Drugs Ltd. pp. A5-A23.
Sybertz, E. 1995, "SCH 48461, a novel inhibitor of cholesterol absorption" Atherosclerosis pp. 311-315.
T. Durst et al., 1971, "Metallation of N-Substituted beta-Lactams. A Method for the Introduction of 3-Substituents into beta-Lactams" Canadian Journal of Chemistry, 50:3196-3201.
T. Durst et al., 1971, "Metallation of N-Substituted β-Lactams. A Method for the Introduction of 3-Substituents into β-Lactams" Canadian Journal of Chemistry, 50:3196-3201.

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040167150A1 (en) * 2000-10-30 2004-08-26 Harris Alan G. Treatment methods
US20030105028A1 (en) * 2000-12-20 2003-06-05 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6627757B2 (en) 2001-03-28 2003-09-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
US20040116510A1 (en) * 2002-03-05 2004-06-17 Nichtberger Steven A. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
US7470678B2 (en) 2002-07-05 2008-12-30 Astrazeneca Ab Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
US20050239766A1 (en) * 2002-07-05 2005-10-27 Astrazeneca Ab Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
US20070021592A1 (en) * 2002-07-19 2007-01-25 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040161838A1 (en) * 2002-07-19 2004-08-19 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20070160666A1 (en) * 2002-07-26 2007-07-12 Merck Sharp & Dohme Limited Pharmaceutical formulation
US20090253675A1 (en) * 2002-07-26 2009-10-08 Merck Sharp & Dohme Limited Pharmaceutical formulation
US20040126423A1 (en) * 2002-07-26 2004-07-01 Moore William D. Pharmaceutical formulation
US7229982B2 (en) 2002-07-26 2007-06-12 Moore William D Pharmaceutical formulation
EP1992343A1 (en) 2002-07-26 2008-11-19 Merck Sharp & Dohme Limited Composition comprising a cholesterol absorption inhibitor, an HMG-CoA reductase inhibitor and a stabilizing agent
US7718643B2 (en) 2002-07-26 2010-05-18 Schering Corporation Pharmaceutical formulation
US7732413B2 (en) 2003-03-07 2010-06-08 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7741289B2 (en) 2003-03-07 2010-06-22 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP2345669A1 (en) 2003-07-17 2011-07-20 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
EP2322548A1 (en) 2003-07-17 2011-05-18 Schering Corporation NPC1L1 (NPC) and methods of use thereof
EP2348046A1 (en) 2003-07-17 2011-07-27 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20050209165A1 (en) * 2003-11-10 2005-09-22 Eduardo Martinez 4-Biarylyl-1-phenylazetidin-2-ones
US20080167255A1 (en) * 2003-11-10 2008-07-10 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
US20080064676A1 (en) * 2003-12-23 2008-03-13 Astrazeneca Ab Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US20050267049A1 (en) * 2003-12-23 2005-12-01 Goulet Mark T Anti-hypercholesterolemic compounds
US20100099657A2 (en) * 2003-12-23 2010-04-22 Astrazeneca Ab Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity
WO2005062824A2 (en) 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
US20070142304A1 (en) * 2003-12-23 2007-06-21 Susanne Alenfalk Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity
US7622449B2 (en) 2003-12-23 2009-11-24 Merck & Co., Inc. Anti-hypercholesterolemic compounds
US7901893B2 (en) 2004-01-16 2011-03-08 Merck Sharp & Dohme Corp. NPC1L1 (NPC3) and methods of identifying ligands thereof
US20100009461A1 (en) * 2004-01-16 2010-01-14 Merck & Co., Inc. Npcil1 (Npc3) And Methods Of Identifying Ligands Thereof
US8236805B2 (en) 2004-12-03 2012-08-07 Intervet Inc. Substituted piperazines as CB1 antagonists
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
US20060161994A1 (en) * 2004-12-15 2006-07-20 Schering Corporation Functional assays for cholesterol absorption inhibitors
US20080287663A1 (en) * 2005-05-06 2008-11-20 Microbia, Inc. Process For Production Of 4-Biphenylyazetidin-2-Ones
US20090292135A1 (en) * 2005-05-09 2009-11-26 Ironwood Pharmaceuticals, Inc. Organometal benzenephosphonate coupling agents
US20080200669A1 (en) * 2005-05-11 2008-08-21 Microbia, Inc. Processes For Production of Phenolic 4-Biphenylylazetidin-2-Ones
US20090099355A1 (en) * 2005-05-25 2009-04-16 Microbia, Inc. Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids
US20100004184A1 (en) * 2005-06-15 2010-01-07 Robert J De Vita Anti-hypercholesterolemic compounds
US7696177B2 (en) 2005-06-15 2010-04-13 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
US20070015807A1 (en) * 2005-06-20 2007-01-18 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
US7635705B2 (en) 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
US20090286830A1 (en) * 2005-06-20 2009-11-19 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
US7846946B2 (en) 2005-06-20 2010-12-07 Schering Plough Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
US20100137273A1 (en) * 2005-06-22 2010-06-03 Astrazeneca Ab Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions
US20100048529A1 (en) * 2005-06-22 2010-02-25 Astrazeneca Ab New 2-Azetidinone Derivatives Useful In The Treatment Of Hyperlipidaemic Conditions
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
EP1922304A2 (en) 2005-09-08 2008-05-21 Teva Pharmaceutical Industries Ltd Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
US20070259845A1 (en) * 2005-09-08 2007-11-08 Kansal Vinod K Processes for the preparation of (3R,4S)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
US20100010212A1 (en) * 2005-09-08 2010-01-14 Vinod Kumar Kansal Processes for the preparation of (3R,4S)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
US7704988B2 (en) 2005-10-05 2010-04-27 Merck & Co., Inc. Anti-hypercholesterolemic compounds
US20090137546A1 (en) * 2005-10-05 2009-05-28 Devita Robert J Anti-Hypercholesterolemic Compounds
US20070078098A1 (en) * 2005-10-05 2007-04-05 Devita Robert J Anti-hypercholesterolemic compounds
US20070161578A1 (en) * 2005-12-21 2007-07-12 Hwa Joyce J Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
US7897601B2 (en) 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
US8212016B2 (en) 2006-02-24 2012-07-03 Schering Corporation NPC1L1 orthologues
US20090098128A1 (en) * 2006-02-24 2009-04-16 Altmann Scott W NPC1L1 orthologues
US7910698B2 (en) 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
US20090069285A1 (en) * 2006-04-27 2009-03-12 Astrazeneca Ab Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitor Activity
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US20090047716A1 (en) * 2007-06-07 2009-02-19 Nurit Perlman Reduction processes for the preparation of ezetimibe
US8623873B2 (en) 2007-06-28 2014-01-07 Intervet Inc. Substituted piperazines as CB1 antagonists
US20090105208A1 (en) * 2007-06-28 2009-04-23 Schering Corporation Substituted Piperazines as CB1 Antagonists
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
US20100204195A1 (en) * 2007-07-27 2010-08-12 Cipla Limited Pharmaceutical Compositions and Process for Making Them
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
US9212175B2 (en) 2009-03-06 2015-12-15 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
US9040688B2 (en) 2009-03-31 2015-05-26 Lupin Limited Intermediates in the preparation of 1,4-diphenyl azetidinone
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
WO2011002424A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
US8623855B2 (en) 2009-08-11 2014-01-07 Zhejiang Hisun Pharmaceutical Co., Ltd. Azetidinone compounds and medical use thereof
WO2011017907A1 (en) 2009-08-11 2011-02-17 浙江海正药业股份有限公司 Azetidinone compounds and medical use thereof
WO2012173504A2 (en) 2011-06-15 2012-12-20 Instytut Chemii Organicznej Polskiej Akademii Nauk Method for synthesis of the substituted azetidinones and intermediates for their synthesis

Also Published As

Publication number Publication date Type
DE122004000026I2 (en) 2005-09-29 grant
FI110321B (en) 2002-12-31 application
NL300132I1 (en) 2003-10-01 grant
DE10399001I2 (en) 2012-05-16 grant
NL300132I2 (en) 2003-11-03 grant
NL300172I1 (en) 2005-04-01 grant
NL300172I2 (en) 2005-08-01 grant
JP2803908B2 (en) 1998-09-24 grant
US5631365A (en) 1997-05-20 grant
LU91160I2 (en) 2005-11-25 grant
FI110321B1 (en) grant
CA2172149C (en) 2000-11-28 grant
DK0720599T3 (en) 1999-11-08 grant
RU2138480C1 (en) 1999-09-27 grant
DK720599T3 (en) grant
LU92544I2 (en) 2015-01-20 grant
DE69418613T2 (en) 1999-09-30 grant
EP0720599B1 (en) 1999-05-19 grant
ES2132432T3 (en) 1999-08-16 grant
US5846966A (en) 1998-12-08 grant
LU91050A9 (en) application
KR186853B1 (en) 1999-05-01 grant
EP0720599A1 (en) 1996-07-10 application
FI961300A0 (en) 1996-03-21 application
LU91160A9 (en) application
DE122004000026I1 (en) 2004-11-18 grant
DE10399001I1 (en) 2003-06-12 grant
LU91050I2 (en) 2004-10-12 grant
DE69418613D1 (en) 1999-06-24 grant
FI961300A (en) 1996-03-21 application
USRE42461E1 (en) 2011-06-14 grant
LU92545I2 (en) 2015-09-21 grant
WO1995008532A1 (en) 1995-03-30 application
US5767115A (en) 1998-06-16 grant
CN1050830C (en) 2000-03-29 grant
FI961300D0 (en) grant
CN1131416A (en) 1996-09-18 application
JPH08509989A (en) 1996-10-22 application

Similar Documents

Publication Publication Date Title
US5698527A (en) Steroidal glycosides as antihyperlipidemic agents
US5354772A (en) Indole analogs of mevalonolactone and derivatives thereof
US6046214A (en) Heterocyclic compounds
US4260627A (en) 1-, 6- And 2-substituted-1-carba-2-penem-3-carboxylic acids
US20030105028A1 (en) Substituted 2-azetidinones useful as hypocholesterolemic agents
US4206219A (en) 6- and 1-Substituted-1-carbadethiapen-2-em-3-carboxylic acid
US20040162323A1 (en) Prostaglandin D2 antagonist
US5306817A (en) Process for the stereospecific synthesis of azetidinones
WO2001064634A1 (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
US4808607A (en) Imidazole analogs of mevalonolactone and derivatives thereof for use in inhibiting cholesterol biosynthesis and lowering blood cholesterol level
US4530793A (en) Processes for the production of penems
WO1996016939A1 (en) Perhydroisoindole derivatives as antagonists of substance p
WO2001064633A1 (en) Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
EP0289380A1 (en) Aryl-heteroaryl-carbinol derivatives having an analgesic activity
US5688787A (en) Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
WO2005021497A2 (en) Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
WO1994014434A1 (en) Endothelin receptor antagonists
US4301074A (en) 6-(1'-Hydroxyethyl)-2-substituted-pen-2-em-3-carboxylic acid
US20070078098A1 (en) Anti-hypercholesterolemic compounds
WO2005090347A1 (en) Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors
WO2005047248A1 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2005044256A1 (en) 2-azetidinones as anti-hypercholesterolemic agents
WO1997016455A1 (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents
WO2005037782A2 (en) Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
WO2002072572A1 (en) Quinolyl propyl piperidine derivatives, the preparation thereof and compositions containing same

Legal Events

Date Code Title Description
CC Certificate of correction
PTEF Application for a patent term extension

Free format text: PRODUCT NAME: ZETIA (EZETIMIBE); REQUESTED FOR 497 DAYS

Filing date: 20021217

Expiry date: 20150616

FPAY Fee payment

Year of fee payment: 8

PTEG Grant of a patent term extension

Free format text: PRODUCT NAME: ZETIA (EZETIMIBE)

Filing date: 20021217

Expiry date: 20150616

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 12

SULP Surcharge for late payment

Year of fee payment: 11

RF Reissue application filed

Effective date: 20100609

AS Assignment

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING CORPORATION;REEL/FRAME:028884/0151

Effective date: 20120502